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EXECUTIVE SUMMARY
The Current Drug Overdose Epidemic in the United States
Drug overdose deaths in the United States more than tripled from 1999 to 2015. The current epidemic of 
drug overdoses began in the 1990s, driven by increasing deaths from prescription opioids that paralleled a 
dramatic increase in the prescribing of such drugs for chronic pain. In 2008, the number of deaths involving 
prescription opioids exceeded the number of deaths from heroin and cocaine combined. Since 2010, 
however, the U.S. has also seen sharp increases in deaths from heroin, synthetic opioids such as fentanyl, 
cocaine, and methamphetamine. In addition to deaths, overdoses from drugs both prescription and illicit are 
responsible for parallel increasing trends in nonfatal emergency department and hospital admissions. 
Morbidity and mortality statistics, however, fail to capture the full extent of the problem with substance use 
disorders in the United States. Survey data indicate that tens of millions of Americans misuse prescription 
opioids, sedatives, tranquilizers, and stimulants. Others use illicit drugs such as heroin, fentanyl, cocaine, and 
methamphetamine. Most persons using heroin have had a history of misusing prescription opioids first. 
The problem with misuse of prescription drugs of various kinds is related to high levels of prescribing of such 
medications. For example, in 2016 prescribers wrote 66.5 opioid and 25.2 sedative prescriptions for every 100 
Americans. 
The purpose of this first annual surveillance report is to summarize the latest information 
available on the national level for various health outcomes, health behaviors, and 
prescribing patterns related to the drug problem in the United States. The most recent year 
of information available is different for different outcomes. The emphasis is on national 
information, but some state information is also presented. This document is intended to 
serve as a resource for persons charged with addressing this ongoing national problem. It 
will be updated annually.
This report presents information on four types of outcomes from the four different data sources:
1 Opioid prescribing, 2006-2016, from QuintilesIMS Health®
2 Drug use, misuse, and substance use disorder, 2014-2015, from the National Survey on Drug Use and 
Health (NSDUH), a product of the Substance Abuse and Mental Health Services Administration
3 Nonfatal overdose hospitalizations and emergency department (ED) visits, 2014, from the Healthcare 
Cost and Utilization Project (HCUP), a product of the Agency for Healthcare Research and Quality (AHRQ) 
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4 Drug overdose mortality, 1999-2015, from the National Vital Statistics System (NVSS) Mortality 
Component, maintained by the National Center for Health Statistics, CDC
 
Opioid Prescribing
Doctors wrote 72.4 opioid prescriptions per 100 persons in 2006. This rate increased 4.1% annually from 2006 
to 2008 and 1.1% annually from 2008 to 2012. It then decreased 4.9% annually from 2012 through 2016, 
reaching a rate of 66.5 per 100 persons in 2016. That year, 19.1 per 100 persons received one or more opioid 
prescriptions, with the average patient receiving 3.5 prescriptions. 
Between 2006 and 2016, the annual prescribing rate per 100 persons for high-dosage opioid prescriptions 
(>90 morphine milligram equivalents (MME)/day) decreased from 11.5 to 6.1, an overall 46.8% reduction and 
an average annual percentage change of 6.6%. The rate leveled off between 2006 and 2009, then decreased 
9.3% annually from 2009 to 2016.
Drug Use, Misuse, and Substance Use Disorder
During 2015, an estimated 47.7 million persons in the United States aged 12 years or older used illicit drugs 
or misused prescription drugs, a rate of 17.8 per 100 persons. This estimate includes use of marijuana, 
cocaine (including crack), heroin, hallucinogens, inhalants, or methamphetamine, and the misuse of 
prescription drugs. Estimated rates of use of illicit drugs in the past year by drug type were: 0.3 per 100 
persons for heroin, 1.8 for cocaine, and 0.6 for methamphetamine. Estimated rates for prescription drug 
misuse by drug type were: 4.7 per 100 persons for prescription pain relievers, 2.3 for tranquilizers, 2.0 for 
stimulants, and 0.6 for sedatives.
Nonfatal Overdose Hospitalizations and Emergency Department (ED) Visits
An estimated 259,665 hospitalizations for nonfatal, unintentional drug poisoning occurred in 2014. Opioid 
poisoning accounted for 20.4% (53,000) of these hospitalizations. Heroin was specified as the involved 
opioid for 21.7% (11,475) of opioid hospitalizations. Cocaine accounted for 13,265, and methamphetamines 
for 8,290 hospitalizations. 
An estimated 418,313 emergency department (ED) visits for nonfatal, unintentional drug poisoning occurred 
in 2014. Opioids accounted for 22.1% (92,262) of these ED visits. Heroin was specified as the involved opioid 
for 58.5% (53,930) of opioid ED visits. Cocaine accounted for 6,424 and methamphetamines for 11,012 visits. 
Drug Overdose Mortality
A record number of drug overdose deaths occurred in 2015: 52,404. While a death may involve more than 
one drug, prescription or illicit opioids were involved in 63.1% of these deaths. Among opioid-involved 
deaths, the most common category was heroin (12,989 deaths), followed by prescription opioids that were 
natural or semi-synthetic (12,727 deaths), synthetic opioids other than methadone (a category that includes 
primarily prescription or illicit fentanyl) (9,580 deaths), and methadone (3,301 deaths). Cocaine was involved 
in 6,784 deaths. Overall, 84.2% of drug overdose deaths were unintentional.
The steady increase in mortality rates for natural or semi-synthetic opioids (e.g., hydrocodone, oxycodone) 
seen from 1999 to 2010 has now started to level off. The rapid increase in heroin deaths that began in 2011 
continued through 2015. The rapid increase in synthetic opioids other than methadone (the category 
containing fentanyl), first noted in 2014, continued through 2015. Death rates involving cocaine have seen 
increasing trends from 2010 to 2015. 
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Limitations
This report has some limitations. Because four distinct data sources were used, terminology and definitions 
are not completely standardized throughout the report. Further, the most recent year of available data varied 
across the data sources. Collectively, these factors limit comparability of information across sections. In 
addition, this report does not address polysubstance use (i.e., the consumption of more than one drug over 
a defined period, simultaneously or at different times for either therapeutic or recreational purposes). For a 
detailed description of the data sources, definitions, and caveats please refer to the technical notes. 
The data from these four sources suggest the following conclusions: 
1 Through 2015, drug overdose remained a large and growing public health crisis in the United States; 
2 Prescription opioid pain relievers were formerly driving the crisis, but by 2015 they shared equal measure 
with heroin, synthetic opioids other than methadone (mostly illicit fentanyl), and—increasingly—
cocaine and methamphetamines; 
3 The leveling off and declines in opioid prescribing rates since 2012 and high-dose prescribing rates 
since 2009 suggest that healthcare providers have responded, becoming more cautious in their opioid 
prescribing practices; and 
4 Additional measures are now urgently needed to address a diverse and evolving array of drug types.
Conclusions
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Data on opioid prescribing estimates from QuintilesIMS Health® were presented for the following outcomes: 
• Annual national estimates of total number and rate for patients who had at least one prescription filled 
for opioids by age and gender, United States, 2014-2016 (Table 1a).
• National total number and rate of opioid prescriptions and morphine milligram equivalents (MME) 
dosage dispensed per 100 persons annually, United States, 2014-2016 (Table 1b).
• Rates of opioid prescriptions dispensed per 100 persons by dosage, type, and state, United States, 2014-
2016 (Table 1c).
• Trend analysis of opioid prescribing rate and dosage, United States, 2006-2016 (Table 1d).
• Trends in opioid prescribing rate and dosage, United States, 2006-2016 (Figure 1a-1d).
All rates presented are per 100 population. For more detailed information, including definitions, please refer 
to the table footnotes and technical notes.
Annual estimates of prescribing rates for all opioids, high-dosage opioids (≥ 90 MME), and days of supply per 
prescription in the United States during 2006-2016 are reported in the Appendix (Supplemental Table 1). In 
addition, average daily MME per prescription, total MME per prescription, MME per capita, and average days’ 
supply per prescription are also presented. 
Patient-Level Opioid Prescribing Rates, United States, 2014-2016 (Table 1a)
• A total of 61,862,364 patients had at least one prescription for opioids filled or refilled in 2016. The total 
rate was 19.1 patients per 100 persons. 
• Among males, the rate was 16.4; among females, it was 21.8 in 2016. 
• Rates per 100 persons by age group were 28.9 for persons aged ≥ 65 years, 25.3 for persons aged 45-54 
years, 15.1 for persons aged 20-24 years, and 11.6 for persons aged 15-19 years in 2016.
Opioid Prescribing Rates and Amount of Opioids Prescribed, United States, 2014-2016 
Prescribing Rates (Table 1b)
• A total of 214,881,622 opioid prescriptions were dispensed by retail pharmacies in 2016. The total opioid 
prescribing rate was 66.5 per 100 persons.
• The long-acting or extended-release (LA/ER) (i.e., slower acting medications with a longer duration of 
pain-relieving action) opioid prescribing rate was 6.3 per 100 persons in 2016. 
• Annual prescribing rates of ≥30 days’ supply was 27.3 per 100 persons in 2016; annual prescribing rates 
of <30 days’ supply was 39.2 in 2016.
Opioid Prescribing
RESULTS OF THE 2017 
SURVEILLANCE REPORT
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• Average number of opioid prescriptions was 3.5 per patient in 2016.
• Average days’ supply per prescription was 18.1 days in 2016. 
Prescribing Dosages (Table 1b)
• 193,655,422,929 morphine milligram equivalents (MME) (i.e., a calculation of the total amount of opioids 
prescribed accounting for differences in drug type and strength) were prescribed in 2016.
• The amount of opioids prescribed was 599.3 MME per person in 2016.
• Average MME per prescription was 901.2 in 2016.
• Average daily MME per prescription was 47.1 in 2016.
• Daily dosage per prescription in 2016: 
 – Low-dosage (< 50 MME/day) prescribing rate was 48.9 per 100 persons.
 – High-dosage (≥ 90 MME/day) prescribing rate was 6.1 per 100 persons.
Opioid Prescribing Rates and Amount of Opioids Prescribed by 50 States and the District of Columbia, 
2014 -2016 (Table 1c)
• Opioid prescribing rates ranged from 32.5 in the District of Columbia to 121.0 per 100 persons in 
Alabama in 2016.
 – States with the highest opioid prescribing rates were Alabama (121.0), Arkansas, (114.6), Tennessee 
(107.5), Mississippi (105.6), and Louisiana (98.1).
 – States with the lowest opioid prescribing rates were Minnesota (46.9), California (44.8), New York (42.7), 
Hawaii (41.9), and District of Columbia (32.5).
• LA/ER opioid prescribing rates ranged from 2.2 in the District of Columbia to 12.7 per 100 persons in 
Delaware in 2016.
 – States with the highest LA/ER opioid prescribing rates were Delaware (12.7), Tennessee (11.0), 
Oklahoma (10.4), Maine (10.3), and Alabama (9.9).
 – States with the lowest LA/ER opioid prescribing rates were Hawaii (4.7), California (4.1), Illinois (4.1), 
Texas (3.8), and District of Columbia (2.2).
• High-dosage opioid prescribing rates (≥ 90 MME/day) ranged from 1.7 in the District of Columbia to 12.0 
per 100 persons in Delaware in 2016.
 – States with the highest high-dosage opioid prescribing rates (≥ 90 MME/day) were Delaware (12.0), 
Utah (10.1), Nevada (10.0), Maine (9.9), and Tennessee (9.8).
 – States with the lowest high-dosage opioid prescribing rates (≥ 90 MME/day) were North Dakota (3.6), 
Minnesota (3.6), Illinois (3.3), Texas (3.0), and District of Columbia (1.7).
Trends in Opioid Prescribing Rates and Amount of Opioids Prescribed, 2006-2016
Annual prescribing rates by dosage 
All opioids
• Between 2006 and 2016, the annual prescribing rate per 100 persons decreased from 72.4 to 66.5 for all 
opioids, an overall 8.1% reduction (Supplemental Table 1). The rate initially increased annually by 4.1% 
from 2006 to 2008 (p<0.05), increased another 1.1% from 2008 to 2012 (p<0.05), and then decreased 
annually by 4.9% from 2012 through 2016 (p<0.05) (Table 1d and Figure 1a). 
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High-dosage opioids (≥ 90 MME/day)
• Between 2006 and 2016, the annual prescribing rate per 100 persons decreased from 11.5 to 6.1 
for high-dosage opioid prescriptions, an overall 46.8% reduction (Supplemental Table 1). The rate 
leveled off between 2006 and 2009, then annually decreased by 9.3% from 2009 to 2016 (p<0.05) 
(Table 1d and Figure 1a). 
Annual prescribing rates by days of supply per prescription (≥30 days and <30 days) 
≥ 30 days’ supply 
• From 2006 through 2016, the annual prescribing rate per 100 persons increased from 17.6 to 27.3 for 
prescriptions with ≥ 30 days of supply, an overall 55.1% increase (Supplemental Table 1). The rate 
increased annually by 9.9% from 2006 through 2010 (p<0.05) and by 2.9% from 2010 through 2013 
(p<0.05), and then annually decreased by 1.3% between 2013 and 2016 (p<0.05) (Table 1d and Figure 1b).
< 30 days’ supply
• During 2006-2016, the annual prescribing rate per 100 persons decreased from 54.7 to 39.2 for 
prescriptions with < 30 days’ supply, an overall 28.4% reduction (Supplemental Table 1). The rate leveled 
off from 2006 through 2008, then decreased annually by 1.2% between 2008 and 2012 (p<0.05), and 
further decreased annually by 7.3% from 2012 to 2016 (p<0.05) (Table 1d and Figure 1b).
Average daily dosage (MME/day) per prescription
• Between 2006 and 2016, average daily MME per prescription decreased from 59.7 to 47.1 for all opioids, an 
overall 21.0% reduction (Supplemental Table 1). The rate decreased annually by 1.0% from 2006 to 2010 
(p<0.05), 4.7% from 2010 to 2013 (p<0.05), and 1.7% from 2013 to 2016 (p<0.05) (Table 1d and Figure 1c).
Average days of supply per prescription 
• Between 2006 and 2016, average days of supply increased from 13.3 to 18.1 days per prescription, an 
overall 35.7% increase (Supplemental Table 1). The rate increased annually by 4.4% from 2006 to 2008 
(p<0.05), 3.4 % from 2008 to 2011 (p<0.05), and 2.5% from 2011 to 2016 (p<0.05) (Table 1d and Figure 1d).
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Self-reported data for persons in the United States aged 12 years or older are presented from the 2015 
National Survey on Drug Use and Health (NSDUH):
• Self-reported prevalence of illicit drug use in past month, persons 12+ years old, heroin and cocaine: 
Numbers in Thousands, United States, 2014 (Table 2a)
• Self-reported prevalence of illicit drug use and prescription drug misuse in past month, persons 12+ 
years old: Numbers in Thousands, United States, 2015 (Table 2b)
• Self-reported prevalence of illicit drug use in past year, persons 12+ years old, heroin and cocaine: 
Numbers in Thousands, United States, 2014 (Table 2c) 
• Self-reported prevalence of illicit drug use and prescription drug misuse in past year, persons 12+ years 
old: Numbers in Thousands, United States, 2015 (Table 2d)
• Self-reported prevalence of prescription drug use (including misuse) in past year, persons 12+ years old, 
by drug type: Numbers in Thousands, United States, 2015 (Table 2e)
• Self-reported prevalence of past year initiation of illicit drug use, persons 12+ years old, heroin, cocaine, 
and methamphetamine: Numbers in Thousands, United States, 2014 and 2015 (Table 2f)
• Self-reported prevalence of past year initiation of prescription drug misuse, persons 12+ years old, by 
prescription drug type: Numbers in Thousands, United States, 2015 (Table 2g)
• Self-reported prevalence of substance use disorder in past year, persons 12+ years old, heroin and 
cocaine: Numbers in Thousands, United States, 2014 (Table 2h)
• Self-reported prevalence of substance use disorder in past year persons 12+ years old, by drug type: 
Numbers in Thousands, United States, 2015 (Table 2i)
All rates are per 100 population and the results of the 2015 analysis are highlighted in this report. For more 
detailed information, including definitions, please refer to the table footnotes and the technical notes.
All Illicit Drug Use and Prescription Drug Misuse
Estimated prevalence for using illicit drugs includes use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine. Prescription drug misuse includes misuse of prescription 
psychotherapeutics (i.e., prescription pain relievers, stimulants, sedatives, and tranquilizers). 
• During 2015, an estimated 47,730,000 persons in the U.S. aged 12 years or older used illicit drugs or 
misused prescription drugs in the past year, with an estimated rate of 17.8 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 20.5; among females, it was 15.3.
 – The estimated rate was 37.5 in persons aged 18-25 years and 26.5 in persons aged 26-34 years.
 – By race and ethnicity, the estimated rates were 20.7 for non-Hispanic blacks, 17.9 for non-Hispanic 
whites, and 17.2 for Hispanics. 
• By U.S. Census region, the estimated rates of illicit drug use/prescription drug misuse in 2015 were 20.9 
per 100 persons in the West, 18.6 in the Northeast, 16.8 in the Midwest, and 16.1 in the South (Table 2d).
• By county type and urbanization, the estimated rate of illicit drug use/prescription drug misuse in 
2015 was 19.0 per 100 persons in large metropolitan counties; the estimated rate was 10.8 in non-
metropolitan, completely rural counties (Table 2d).
Drug Use, Misuse, and Substance Use Disorder
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Opioids
Estimated prevalence for opioids includes use of heroin and misuse of prescription pain relievers (e.g., 
oxycodone, hydrocodone). Estimates are provided for the prevalence of past year initiation of drug use and 
misuse and the prevalence of past year substance use disorder, for heroin and prescription pain relievers.
Heroin
• During 2015, an estimated 828,000 persons in the U.S. aged 12 years or older used heroin in the past 
year, with an estimated rate of 0.3 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 0.4; among females, it was 0.2.
 – The estimated rate was 0.8 in persons aged 26-34 years and 0.6 in persons aged 18-25 years.
 – By race and ethnicity, the estimated rates were 0.4 for non-Hispanic blacks, and 0.3 for non-Hispanic 
whites and for Hispanics. 
• By U.S. Census region, the estimated rates of heroin use in 2015 were 0.5 per 100 persons in the 
Northeast, 0.4 in the West, 0.3 in the Midwest, and 0.2 in the South (Table 2d).
• By county type and urbanization, the estimated rate of heroin use in 2015 was 0.4 per 100 persons 
both in small metropolitan counties with a population of less than 250,000 and non-metropolitan, 
urbanized counties; the estimated rate was 0.1 per 100 persons in non-metropolitan, completely rural 
counties (Table 2d).
• An estimated 135,000 persons in the U.S. aged 12 years or older initiated use of heroin during 2015, with 
an estimated rate of 0.1 per 100 persons (Table 2f). 
• During 2015, an estimated 591,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving heroin, with an estimated rate of 0.2 per 100 persons (Table 2i).
Prescription Pain Relievers (e.g., oxycodone, hydrocodone)
• During 2015, an estimated 12,462,000 persons aged 12 years or older in the U.S. misused prescription 
pain relievers in the past year, with an estimated rate of 4.7 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 5.3; among females, it was 4.0.
 – The estimated rate was 8.5 in persons aged 18-25 years and 7.4 in persons aged 26-34 years.
 – By race and ethnicity, the estimated rates were 5.0 for Hispanics, 4.8 for non-Hispanic whites, and 4.4 
for non-Hispanic blacks.
• By U.S. Census region, the estimated rates of prescription pain relievers misuse in 2015 were 5.3 per 100 
persons in the West, 4.6 in the South, 4.4 in the Midwest, and 4.2 in the Northeast (Table 2d).
• By county type and urbanization, the estimated rate of prescription pain relievers misuse in 2015 was 
4.9 per 100 persons both in small metropolitan counties with a population of less than 250,000 and 
non-metropolitan, urbanized counties; the estimated rate was 3.2 per 100 persons in non-metropolitan, 
completely rural counties (Table 2d).
• An estimated 2,126,000 persons in the U.S. aged 12 years or older initiated misuse of prescription pain 
relievers during 2015, with an estimated rate of 0.8 per 100 persons (Table 2g). 
• During 2015, an estimated 2,038,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving prescription pain relievers, with an estimated rate of 0.8 per 100 persons (Table 2i). 
Stimulants
Estimated prevalence for stimulants includes use of cocaine and methamphetamine and misuse of 
prescription stimulants. Estimates are provided for the prevalence of past year initiation of drug use and 
misuse and the prevalence of past year substance use disorder, for cocaine, methamphetamine, and 
prescription stimulants.
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Cocaine
• During 2015, an estimated 4,828,000 persons in the U.S. aged 12 years or older used cocaine in the past 
year, with an estimated rate of 1.8 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 2.4; among females, it was 1.3.
 – The estimated rate was 5.4 in persons aged 18-25 years and 3.2 in persons aged 26-34 years.
 – By race and ethnicity, the estimated rates were 2.4 for non-Hispanic blacks, 1.8 for non-Hispanic whites, 
and 1.7 for Hispanics. 
• By U.S. Census region, the estimated rates of cocaine use in 2015 were 2.2 per 100 persons in the 
Northeast, 2.1 in the West, 1.7 in the South, and 1.4 in the Midwest (Table 2d).
• By county type and urbanization, the estimated rate of cocaine use in 2015 was 2.0 per 100 persons in 
large metropolitan counties; the estimated rate was 0.8 per 100 persons in non-metropolitan, completely 
rural counties (Table 2d).
• An estimated 968,000 persons in the U.S. aged 12 years or older initiated use of cocaine during 2015, 
with an estimated rate of 0.4 per 100 persons (Table 2f). 
• During 2015, an estimated 896,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving cocaine, with an estimated rate of 0.3 per 100 persons (Table 2i). 
Methamphetamine
• During 2015, an estimated 1,713,000 persons in the U.S. aged 12 years or older used methamphetamine 
in the past year, with an estimated rate of 0.6 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 0.9; among females, it was 0.4. 
 – The estimated rate was 1.1 in persons aged 26-34 years and in persons 35-39 years, and 1.0 in persons 
aged 45-49 years. 
 – By race and ethnicity, the estimated rates were 0.7 for non-Hispanic whites, 0.6 for Hispanics, and 0.4 
for non-Hispanic blacks. 
• By U.S. Census region, the estimated rates of methamphetamine use in 2015 were 1.2 per 100 persons in 
the West, 0.6 in the South, 0.4 in the Midwest, and 0.2 in the Northeast (Table 2d).
• By county type and urbanization, the estimated rate of methamphetamine use in 2015 was 1.3 per 100 
persons in non-metropolitan, less urbanized counties; the estimated rate was 0.5 per 100 persons in 
large metropolitan counties (Table 2d).
• An estimated 225,000 persons in the U.S. aged 12 years or older initiated use of methamphetamine 
during 2015, with an estimated rate of 0.1 per 100 persons (Table 2f). 
• During 2015, an estimated 872,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving methamphetamine, with an estimated rate of 0.3 per 100 persons (Table 2i). 
Prescription Stimulants
• During 2015, an estimated 5,251,000 persons in the U.S. aged 12 years or older misused prescription 
stimulants in the past year, with an estimated rate of 2.0 per 100 persons (Table 2d).
 – Among males, the estimated rate was 2.3; among females, it was 1.6.
 – The estimated rate was 7.3 in persons aged 18-25 years and 3.4 in persons aged 26-34 years.
 – By race and ethnicity, the estimated rates were 2.4 for non-Hispanic whites, 1.5 for Hispanics, and 0.7 
for non-Hispanic blacks. 
• By U.S. Census region, the estimated rates of prescription stimulant misuse in 2015 were 2.2 per 100 
persons in the Midwest, 2.1 in the Northeast, 2.0 in the South, and 1.6 in the West (Table 2d).
• By county type and urbanization, the estimated rate of prescription stimulant misuse in 2015 was 2.3 per 
100 persons in non-metropolitan, urbanized counties; the estimated rate was 0.7 per 100 persons in non-
metropolitan, completely rural counties (Table 2d).
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• An estimated 1,260,000 persons in the U.S. aged 12 years or older initiated misuse of prescription 
stimulants during 2015, with an estimated rate of 0.5 per 100 persons (Table 2g). 
• During 2015, an estimated 426,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving prescription stimulants, with an estimated rate of 0.2 per 100 persons (Table 2i).
Other Drugs
Estimated prevalence for other drugs includes misuse of prescription sedatives and prescription tranquilizers. 
Estimates are provided for the prevalence of past year initiation of drug misuse and the prevalence of past 
year substance use disorder, for prescription sedatives and prescription tranquilizers.
Prescription Sedatives
• During 2015, an estimated 1,511,000 persons in the U.S. aged 12 years or older misused prescription 
sedatives in the past year, with an estimated rate of 0.6 per 100 persons (Table 2d). 
 – Among females, the estimated rate was 0.7; among males, it was 0.5. 
 – The estimated rate was 0.9 in persons aged 26-34 years and 0.8 both in persons 18-25 years and in 
persons 55-59 years. 
 – By race and ethnicity, the estimated rates were 0.7 for non-Hispanic whites, 0.4 for Hispanics, and 0.2 
for non-Hispanic blacks. 
• By U.S. Census region, the estimated rates of prescription sedative misuse in 2015 were 0.6 per 100 persons 
in the Northeast, South, and West; the estimated rate was 0.4 per 100 persons in the Midwest (Table 2d).
• By county type and urbanization, the estimated rate of prescription sedatives misuse in 2015 was 0.8 per 
100 persons in non-metropolitan, urbanized counties; the estimated rate was 0.1 per 100 persons in non-
metropolitan, completely rural counties (Table 2d).
• An estimated 425,000 persons in the U.S. aged 12 years or older initiated misuse of prescription sedatives 
in 2015, with an estimated rate of 0.2 per 100 persons (Table 2g).
• During 2015, an estimated 154,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving prescription sedatives, with an estimated rate of 0.1 per 100 persons (Table 2i).
Prescription Tranquilizers
• During 2015, an estimated 6,050,000 persons in the U.S. aged 12 years or older misused prescription 
tranquilizers in the past year, with an estimated rate of 2.3 per 100 persons (Table 2d). 
 – Among males, the estimated rate was 2.4; among females, it was 2.1.
 – The estimated rate was 5.4 in persons aged 18-25 years and 3.5 in persons aged 26-34 years.
 – By race and ethnicity, the estimated rates were 2.6 for non-Hispanic whites, 2.0 for Hispanics, and 1.5 
for non-Hispanic blacks. 
• By U.S. Census region, the estimated rates of prescription tranquilizer misuse were 2.6 per 100 persons in 
the South, 2.3 in the Northeast, 2.1 in the West, and 1.9 in the Midwest (Table 2d).
• By county type and urbanization, the estimated rate of prescription tranquilizer misuse in 2015 was 2.7 
per 100 persons in non-metropolitan, urbanized counties; the estimated rate was 1.2 per 100 persons in 
non-metropolitan, completely rural counties (Table 2d).
• An estimated 1,437,000 persons in the U.S. aged 12 years or older initiated misuse of prescription 
tranquilizers during 2015, with an estimated rate of 0.5 per 100 persons (Table 2g).
• During 2015, an estimated 688,000 persons in the U.S. aged 12 years or older had a substance use 
disorder involving prescription tranquilizers, with an estimated rate of 0.3 per 100 persons (Table 2i).
CDC National Center for Injury Prevention and Control  |  2017Annual Surveillance Report of Drug-Related Risks and Outcomes  |  United States
16
Data on unintentional, nonfatal, drug-related poisonings for all persons in the U.S. are presented from 2014 
survey data from the Healthcare Cost and Utilization Project (HCUP):
• Estimated number and age-adjusted rates of hospitalizations overall and by individual drugs by 
demographic characteristics (Table 3a) 
• Estimated number and age-adjusted rates of emergency department visits overall and by individual 
drugs by demographic characteristics (Table 3b)
• Information on primary payer for drug-related poisoning hospitalizations and ED visits (Table 3c)
As poisoning-related hospitalizations and ED visits may involve more than one type of drug, and external 
cause of injury codes were used in addition to principal diagnosis codes, the categories of unintentional, 
drug-related poisoning are not mutually exclusive. All rates are per 100,000 population and age-adjusted, 
except the rates for age. For more detailed information, including definitions, please refer to the table 
footnotes and the technical notes.
Rates of hospitalizations (Supplemental Table 2a) and emergency department visits (Supplemental 
Table 2b) due to unintentional, nonfatal, drug-related overdoses for 2014 that are not age-adjusted are 
presented in the Appendix. 
 
All Drugs
Hospitalizations
• During 2014, an estimated 259,665 hospitalizations occurred for all unintentional, drug-related 
poisonings in the U.S., with an estimated age-adjusted rate of 79.2 per 100,000 (Table 3a).
 – Among females, the age-adjusted rate was 87.0; among males, it was 71.2. 
 – The rate was 120.5 in persons aged 45-54 years and 105.0 in persons aged 55-64 years. 
• By region, age-adjusted hospitalization rates for all unintentional, drug-related poisonings were 84.7 in 
the Midwest, 82.3 in the South, 81.7 per 100,000 in the Northeast, and 68.0 in the West (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for all unintentional, drug-related poisonings were 
87.9 in small metropolitan areas and 72.3 in large fringe metropolitan areas (Table 3a).
Emergency Department (ED) Visits
• During 2014, an estimated 418,313 ED visits occurred for all unintentional, drug-related poisonings in 
the U.S., with an estimated age-adjusted rate of 133.7 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 127.9; among females, it was 139.5. 
 – The rate was 221.8 in persons aged 15-19 years and 211.3 in persons aged 20-24 years. 
• By region, age-adjusted ED visit rates for all unintentional, drug-related poisonings were 154.0 per 
100,000 in the Northeast, 153.7 in the Midwest, 128.5 in the West, and 117.0 in the South. (Table 3b). 
• By urbanization, age-adjusted ED visit rates for all unintentional, drug-related poisonings were 161.4 
in micropolitan (i.e., town/city; nonmetro) areas and 106.5 per 100,000 in large central metropolitan 
areas (Table 3b).
Nonfatal Overdose Hospitalizations and  
Emergency Department (ED) Visits
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Opioids 
All Opioids
Hospitalizations
• During 2014, an estimated 53,000 hospitalizations occurred for unintentional, opioid-related poisonings 
in the U.S., with an estimated age-adjusted rate of 15.6 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 15.7; among females, it was 15.4. 
 – The rate was 28.9 in persons aged 55-64 years and 25.0 in persons aged 45-54 years. 
• By region, age-adjusted hospitalization rates for unintentional, opioid-related poisonings were 17.8 per 
100,000 in the Northeast, 15.9 in the Midwest, 15.3 in the South, and 14.4 in the West (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for unintentional, opioid-related poisonings were 17.3 
in medium metropolitan areas and 13.5 in noncore areas (not metropolitan or micropolitan) (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 92,262 ED visits occurred for unintentional, opioid-related poisonings in the 
U.S., with an estimated age-adjusted rate of 28.9 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 36.3; among females, it was 21.6. 
 – The rate was 71.1 in persons aged 20-24 years and 70.0 in persons aged 25-34 years.  
• By region, age-adjusted ED visit rates for unintentional, opioid-related poisonings were 49.9 per 100,000 
in the Northeast, 37.9 in the Midwest, 20.9 in the South, and 19.0 in the West (Table 3b). 
• By urbanization, age-adjusted ED visit rates for unintentional, opioid-related poisonings were 35.9 in 
large fringe metropolitan areas and 20.5 in noncore areas (not metropolitan or micropolitan areas) 
(Table 3b). 
Heroin
Hospitalizations
• During 2014, an estimated 11,475 hospitalizations occurred for unintentional, heroin-related poisonings 
in the U.S., with an estimated age-adjusted rate of 3.6 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 5.0; among females, it was 2.1. 
 – The rate was 9.8 in persons aged 25-34 years and 9.6 in persons aged 20-24 years.  
• By region, age-adjusted hospitalization rates for unintentional, heroin-related poisonings were 6.2 per 
100,000 in the Northeast, 5.1 in the Midwest, 2.4 in the South, and 2.2 in the West (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for unintentional, heroin-related poisonings were 
4.7 in large fringe metropolitan areas and 1.6 in noncore areas (not metropolitan or micropolitan 
areas) (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 53,930 ED visits occurred for unintentional, heroin-related poisonings in the 
U.S., with an estimated age-adjusted rate of 17.1 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 24.0; among females, it was 10.2. 
 – The rate was 53.5 in persons aged 20-24 years and 51.5 in persons aged 25-34 years.  
• By region, age-adjusted ED visit rates for unintentional, heroin-related poisonings were 37.7 per 100,000 
in the Northeast, 24.8 in the Midwest, 9.9 in the South, and 7.0 in the West (Table 3b). 
• By urbanization, age-adjusted ED visit rates for unintentional, heroin-related poisonings were 25.5 in large 
fringe metropolitan areas and 6.1 in noncore areas (not metropolitan or micropolitan areas) (Table 3b). 
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Methadone
Hospitalizations
• During 2014, an estimated 4,580 hospitalizations occurred for methadone-related poisonings in the U.S., 
with an estimated age-adjusted rate of 1.4 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 1.5; among females, it was 1.2. 
 – The rate was 2.9 in persons aged 55-64 years and 2.5 in persons aged 45-54 years.  
• By region, age-adjusted hospitalization rates for unintentional, methadone-related poisonings were 1.7 
per 100,000 in the Northeast, 1.4 in the West, 1.3 in the South, and 1.2 in the Midwest (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for methadone-related poisonings were 1.5 per 
100,000 in large central and medium metropolitan areas and 1.1 large fringe metropolitan and in 
noncore areas (not metropolitan or micropolitan areas) (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 2,921 ED visits occurred for unintentional, methadone-related poisonings in 
the U.S., with an estimated age-adjusted rate of 0.9 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 1.0; among females, it was 0.8. 
 – The rate was 1.6 in persons aged 25-34 years and 1.4 in persons aged 35-44 years.  
• By region, age-adjusted ED visit rates for unintentional, methadone-related poisonings were 1.2 in the 
West, 1.0 per 100,000 in the Northeast, 0.8 in the South, and 0.7 in the Midwest (Table 3b). 
• By urbanization, age-adjusted ED visit rates for unintentional, methadone-related poisonings were 1.1 
per 100,000 in large central metropolitan areas and noncore areas (not metropolitan or micropolitan) 
and 0.6 in large fringe metropolitan areas (Table 3b).
Other Opioids (e.g., unspecified opioids, opium) 
Hospitalizations
• During 2014, an estimated 37,125 hospitalizations occurred for other unintentional, opioid-related 
poisonings in the U.S., with an estimated age-adjusted rate of 10.7 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 9.2; among females, it was 12.1. 
 – The rate was 23.7 in persons aged 55-64 years and 19.6 in persons aged 65 years or older. 
• By region, age-adjusted hospitalization rates for other opioid-related poisonings were 11.6 in the South, 
10.8 in the West, 10.0 per 100,000 in the Northeast, and 9.7 in the Midwest, (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for other opioid-related poisonings were 12.3
 in micropolitan areas (i.e., town/city; nonmetro) and 9.6 per 100,000 in large fringe metropolitan
 areas (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 35,690 ED visits occurred for other unintentional, opioid-related poisonings in 
the U.S., with an estimated age-adjusted rate of 11.0 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 11.4; among females, it was 10.6. 
 – The rate was 17.2 in persons aged 25-34 years and 16.8 in persons aged 20-24 years. 
• By region, age-adjusted ED visit rates for other unintentional, opioid-related poisonings were 12.6 per 
100,000 in the Midwest, 11.3 in the Northeast, 10.9 in the West and 10.2 in the South (Table 3b). 
• By urbanization, age-adjusted ED rates for other unintentional, opioid-related poisonings were 14.1 in 
medium metropolitan areas and 8.5 in large central metropolitan areas (Table 3b). 
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Stimulants
Cocaine
Hospitalizations
• During 2014, an estimated 13,265 hospitalizations occurred for unintentional, cocaine-related 
poisonings in the U.S., with an estimated age-adjusted rate of 4.0 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 5.5; among females, it was 2.6. 
 – The rate was 10.8 in persons aged 45-54 years and 7.2 in persons aged 55-64 years. 
• By region, age-adjusted hospitalization rates for cocaine-related poisonings were 7.5 per 100,000 in the 
Northeast, 4.3 in the South, 3.3 in the Midwest, and 1.5 in the West (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for cocaine-related poisonings were 6.9 per 
100,000 in large central metropolitan areas and 1.4 in noncore areas (not metropolitan or micropolitan 
areas) (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 6,424 ED visits occurred for unintentional, cocaine-related poisonings in the 
U.S., with an estimated age-adjusted rate of 2.1 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 2.9; among females, it was 1.3. 
 – The rate was 3.8 in persons aged 25-34 years and 3.4 in persons aged 35-44 years. 
• By region, age-adjusted ED visit rates for unintentional, cocaine-related poisonings were 2.7 in the 
South, 2.1 per 100,000 in the Northeast, 1.8 in the Midwest, and 1.4 in the West (Table 3b). 
• By urbanization, age-adjusted ED visit rates for unintentional, cocaine-related poisonings were 2.6 
per 100,000 in large central metropolitan areas and 1.3 in micropolitan areas and noncore areas (not 
metropolitan or micropolitan areas) (Table 3b). 
Methamphetamine
Hospitalizations
• During 2014, an estimated 8,290 hospitalizations occurred for unintentional, methamphetamine-
related poisonings in the U.S., with an estimated age-adjusted rate of 2.7 per 100,000 (Table 3a). 
 – Among males, the age-adjusted rate was 3.5; among females, it was 1.9. 
 – The rate was 6.2 in persons aged 25-34 years and 4.5 in persons aged 20-24 years.
• By region, age-adjusted hospitalization rates for unintentional, methamphetamine-related poisonings 
were 4.7 in the West, 2.5 in the South, 2.0 in the Midwest, and 1.1 per 100,000 in the Northeast (Table 3a). 
• By urbanization, age-adjusted hospitalization rates for unintentional, methamphetamine-related 
poisonings were 3.4 in small metropolitan areas and 2.0 per 100,000 in large fringe metropolitan 
 areas (Table 3a). 
Emergency Department (ED) Visits
• During 2014, an estimated 11,012 ED visits occurred for unintentional, methamphetamine-related 
poisonings in the U.S., with an estimated age-adjusted rate of 3.6 per 100,000 (Table 3b). 
 – Among males, the age-adjusted rate was 4.4; among females, it was 2.8. 
 – The rate was 8.2 in persons aged 20-24 years and 7.0 in persons aged 25-34 years. 
• By region, age-adjusted ED visit rates for unintentional, methamphetamine-related poisonings were 5.1 
in the West, 3.7 in the Midwest, 3.2 in the South, and 2.2 per 100,000 in the Northeast (Table 3b). 
• By urbanization, age-adjusted ED visit rates for unintentional, methamphetamine-related poisonings 
were 5.0 in noncore areas (not metropolitan or micropolitan areas) and 2.3 in per 100,000 in large fringe 
metropolitan areas (Table 3b). 
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Statistics on drug overdose deaths for all persons in the U.S. are presented from the National Vital Statistics 
System, mortality files: 
• Number and age-adjusted rates of all drug overdose deaths and by selected drugs by demographic 
characteristics and intent in 2015 (Table 4a)
• Number and age-adjusted rates of all drug overdose deaths and by selected drugs by demographic 
characteristics and intent in 2014 (Table 4b)
• Trends in age-adjusted rates of drug overdose deaths and drug overdose deaths involving any opioid, of 
all intents and of unintentional intent, by year, 1999–2015 (Figure 2a)
• Trends in drug overdose deaths involving natural and semi-synthetic opioids, methadone and synthetic 
opioids other than methadone, heroin, and selected stimulants, 1999–2015 (Figure 2b)
• Drug overdose deaths by age category and drug class, 2015 (Figure 2c)
• Age-adjusted rates of drug overdose deaths, by state, 2014 (Figure 2d)
• Age-adjusted rates of drug overdose deaths, by state, 2015 (Figure 2e)
Rates are calculated per 100,000 population age-adjusted to the 2000 U.S. standard population using the 
vintage year population of the data year. For more detailed information, including definitions, please refer to 
table footnotes and the technical notes. 
Data supporting Figures 2a-2c and 2e are presented in Supplemental Tables supporting Figure 2a, 2b, 2c, 
and 2d in the Appendix.
All Drug Overdose Deaths 
• During 2015, a total of 52,404 persons in the United States died from drug overdoses; the age-adjusted 
rate was 16.3 (per 100,000). 
 – Among males, the rate was 20.8; among females, it was 11.8. 
 – The rate was 30.0 in persons aged 45-54 years and 28.3 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 21.1 in non-Hispanic whites, 12.2 in non-Hispanic blacks, and 
7.7 in Hispanics. 
• By region, age-adjusted death rates from drug overdoses were 19.8 per 100,000 in the Northeast, 17.8 in 
the Midwest, 15.5 in the South, and 13.9 in the West. 
• By urbanization, age-adjusted death rates from drug overdoses were 18.3 in medium metropolitan areas 
and 14.8 per 100,000 in large central metropolitan areas. 
• In 2015, a total of 44,126 persons in the U.S. died from unintentional drug overdoses; the age-adjusted 
rate was 13.8 per 100,000. A total of 2,979 persons died of drug overdoses of undetermined intent; the 
age-adjusted rate was 0.9. 
Drug Overdose Mortality
Primary Source of Payment for Medically Attended, Nonfatal, Unintentional 
Drug Overdoses (Table 3c)
• During 2014, 30.3% of hospitalizations for all unintentional drug-related poisonings listed Medicaid as 
the primary source of payment; 31.0% listed Medicare, and 23.0% listed private insurance.
• During 2014, 35.5% of ED visits for all unintentional drug-related poisonings listed Medicaid as the 
primary source of payment; 16.0% listed Medicare, and 27.4% listed private insurance.
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Opioid Overdose Deaths 
• During 2015, a total of 33,091 persons in the United States died from drug overdoses involving opioids 
(e.g., oxycodone, hydrocodone, heroin); the age-adjusted rate was 10.4 (per 100,000). 
 – Among males, the rate was 13.7; among females, it was 7.1. 
 – The rate was 19.4 in persons aged 25-34 years and 18.4 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 13.9 in non-Hispanic whites, 6.6 in non-Hispanic blacks, and 
4.6 in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving opioids were 13.6 per 100,000 in the 
Northeast, 12.2 in the Midwest, 9.8 in the South, and 7.4 in the West. 
• By urbanization, age-adjusted death rates from drug overdoses involving opioids were 11.8 in medium 
metropolitan areas and 9.4 per 100,000 in large central metropolitan areas. 
• In 2015, a total of 29,382 persons in the U.S. died from unintentional drug overdoses involving 
opioids; the age-adjusted rate was 9.3 per 100,000. A total of 1,857 persons died of drug overdoses of 
undetermined intent involving opioids; the age-adjusted rate was 0.6. 
Prescription Opioid Overdose Deaths 
• During 2015, a total of 15,281 persons in the United States died from drug overdoses involving 
prescription opioids (e.g., oxycodone, hydrocodone); the age-adjusted rate was 4.7 (per 100,000). 
 – Among males, the rate was 5.4; among females, it was 4.0. 
 – The rate was 9.5 in persons aged 45-54 years and 8.4 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 6.4 in non-Hispanic whites, 2.6 in non-Hispanic blacks, and 1.8 
in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving prescription opioids were 5.2 in the 
South, 4.5 per 100,000 in the Northeast and West, and 4.2 in the Midwest. 
• By urbanization, age-adjusted death rates from drug overdoses involving prescription opioids were 5.9 
in noncore areas and 4.1 per 100,000 in large central metropolitan areas. 
• In 2015, a total of 12,923 persons in the U.S. died from unintentional drug overdoses involving 
prescription opioids; the age-adjusted rate was 4.0 per 100,000. A total of 985 persons died of drug 
overdoses of undetermined intent involving prescription opioids; the age-adjusted rate was 0.3. 
Natural and Semi-synthetic Opioid Overdose Deaths 
• During 2015, a total of 12,727 persons in the United States died from drug overdoses involving natural 
and semi-synthetic opioids (e.g., oxycodone, hydrocodone, morphine); the age-adjusted rate was 3.9 
(per 100,000). 
 – Among males, the rate was 4.4; among females, it was 3.4. 
 – The rate was 8.1 in persons aged 45-54 years and 6.9 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 5.3 in non-Hispanic whites, 2.1 in non-Hispanic blacks, and 1.5 
in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving natural and semi-synthetic opioids 
were 4.4 per 100,000 in the South, 3.8 in the West, 3.6 in the Northeast, and 3.4 in the Midwest. 
• By urbanization, age-adjusted death rates from drug overdoses involving natural and semi-synthetic 
opioids were 5.1 per 100,000 in noncore areas and 3.3 in large central metropolitan areas. 
• In 2015, a total of 10,621 persons in the U.S. died from unintentional drug overdoses involving natural 
and semi-synthetic opioids; the age-adjusted rate was 3.3 per 100,000. A total of 807 persons died of 
drug overdoses of undetermined intent involving natural and semi-synthetic opioids; the age-adjusted 
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rate was 0.3. 
Methadone Overdose Deaths 
• During 2015, a total of 3,301 persons in the United States died from drug overdoses involving 
methadone; the age-adjusted rate was 1.0 (per 100,000). 
 – Among males, the rate was 1.2; among females, it was 0.8. 
 – The rate was 2.0 in persons aged 45-54 years and 1.8 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 1.4 in non-Hispanic whites, 0.6 in non-Hispanic blacks, and 0.5 
in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving methadone were 1.1 per 100,000 in 
the Northeast, and 1.0 in the Midwest, the South, and the West. 
• By urbanization, age-adjusted death rates from drug overdoses involving methadone were 1.2 per 
100,000 in medium metropolitan and noncore areas and 0.9 in large fringe metropolitan areas. 
• In 2015, a total of 2,955 persons in the U.S. died from unintentional drug overdoses involving 
methadone; the age-adjusted rate was 0.9 per 100,000. A total of 237 persons died of drug overdoses of 
undetermined intent involving methadone; the age-adjusted rate was 0.1. 
Synthetic Opioids (other than Methadone) Overdose Deaths
• During 2015, a total of 9,580 persons in the United States died from drug overdoses involving synthetic 
opioids other than methadone (e.g., fentanyl, tramadol); the age-adjusted rate was 3.1 (per 100,000). 
 – Among males, the rate was 4.2; among females, it was 1.9. 
 – The rate was 6.6 in persons aged 25-34 years and 5.6 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 4.2 in non-Hispanic whites, in non-Hispanic blacks, 2.1 and 
Hispanics, 0.9.
• By region, age-adjusted death rates from drug overdoses involving synthetic opioids other than 
methadone were 5.6 per 100,000 in the Northeast, 3.9 in the Midwest, 2.8 in the South, and 0.9 in the West. 
• By urbanization, age-adjusted death rates from drug overdoses involving synthetic opioids other 
than methadone were 3.9 per 100,000 in large fringe metropolitan areas and 2.4 in large central 
metropolitan areas. 
• In 2015, a total of 8,609 persons in the U.S. died from unintentional drug overdoses involving synthetic 
opioids other than methadone; the age-adjusted rate was 2.8 per 100,000. A total of 544 persons died 
of drug overdoses of undetermined intent involving synthetic opioids other than methadone; the age-
adjusted rate was 0.2. 
Heroin Overdose Deaths  
• During 2015, a total of 12,989 persons in the United States died from drug overdoses involving heroin; 
the age-adjusted rate was 4.1 (per 100,000). 
 – Among males, the rate was 6.3; among females, it was 2.0. 
 – The rate was 9.7 in persons aged 25-34 years and 7.4 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 5.4 in non-Hispanic whites, 3.1 in non-Hispanic blacks, and 2.3 
in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving heroin were 6.3 per 100,000 in the 
Northeast, 6.1 in the Midwest, 3.2 in the South, and 2.4 in the West. 
• By urbanization, age-adjusted death rates from drug overdoses involving heroin were 5.0 per 100,000 in 
large fringe metropolitan areas and 2.1 in noncore areas. 
• In 2015, a total of 12,284 persons in the U.S. died from unintentional drug overdoses involving 
heroin; the age-adjusted rate was 3.9 per 100,000. A total of 586 persons died of drug overdoses of 
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undetermined intent involving heroin; the age-adjusted rate was 0.2. 
Selected Stimulant Overdose Deaths 
Cocaine Overdose Deaths
• During 2015, a total of 6,784 persons in the United States died from drug overdoses involving cocaine; 
the age-adjusted rate was 2.1 (per 100,000). 
 – Among males, the rate was 3.1; among females, it was 1.2. 
 – The rate from cocaine was 4.3 in persons aged 45-54 years and 3.8 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 4.0 in non-Hispanic blacks, 2.2 in non-Hispanic whites, and 1.3 
in Hispanics. 
• By region, age-adjusted death rates from drug overdoses involving cocaine were 3.3 per 100,000 in the 
Northeast, 2.5 in the Midwest, 2.2 in the South, and 0.9 in the West. 
• By urbanization, age-adjusted death rates from drug overdoses involving cocaine were 2.7 per 100,000 
in large central metropolitan areas and 0.9 in noncore areas. 
• In 2015, a total of 6,467 persons in the U.S. died from unintentional drug overdoses involving 
cocaine; the age-adjusted rate was 2.0 per 100,000. A total of 208 persons died of drug overdoses of 
undetermined intent involving cocaine; the age-adjusted rate was 0.1. 
Psychostimulants with Abuse Potential Overdose Deaths
• In 2015, a total of 5,716 persons in the United States died from drug overdoses involving 
psychostimulants with abuse potential (i.e., methamphetamine, 3,4-methylenedioxy-methamphetamine 
(MDMA, Ecstasy)); the age-adjusted rate was 1.8 (per 100,000). 
 – Among males, the rate was 2.5; among females, it was 1.1. 
 – The death rate from psychostimulants with abuse potential was 3.5 in persons aged 45-54 years and 
3.3 in persons aged 35-44 years. 
 – By race and ethnicity, the death rate was 2.2 in non-Hispanic whites, 0.8 in non-Hispanic blacks, and 1.4 
in Hispanics.
• By region, age-adjusted death rates from drug overdoses involving psychostimulants with abuse 
potential were 3.9 per 100,000 in the West, 1.5 in the South, 1.1 in the Midwest, and 0.5 in the Northeast. 
• By urbanization, age-adjusted death rates from drug overdoses involving psychostimulants with abuse 
potential were 2.3 per 100,000 in noncore areas and 1.2 in large fringe metropolitan areas. 
• In 2015, a total of 5,307 persons in the U.S. died from unintentional drug overdoses involving 
psychostimulants with abuse potential; the age-adjusted rate was 1.7 per 100,000. A total of 174 persons 
died of drug overdoses of undetermined intent involving psychostimulants with abuse potential; the 
age-adjusted rate was 0.05. 
Mortality Trends
Age-adjusted rates of drug overdose deaths and drug overdose deaths involving any opioid, for all 
intents and unintentional intent, by year, United States, 1999–2015 (Figure 2a) 
• The age-adjusted rate of drug overdose deaths increased from 6.1 per 100,000 population in 1999 to 
16.3 in 2015 (p<0.05). Unintentional drug overdose death rates increased from 4.0 per 100,000 in 1999 to 
13.8 in 2015 (p<0.05). 
• The rate of drug overdose deaths involving any type of opioid increased from 2.9 per 100,000 in 1999 to 
10.4 in 2015 (p<0.05). Unintentional drug overdose death rates involving any type of opioid increased 
from 2.1 per 100,000 in 1999 to 9.3 per 100,000 in 2015 (p<0.05)
• During 1999 to 2015, rate increases for overall drug overdoses, unintentional drug overdoses, drug 
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overdoses of all intents involving any opioid, and unintentional drug overdoses involving any opioid 
were largest from 2013 to 2015. 
 – The rate increased on average from 2013 to 2015 by 9% per year for overall drug overdose deaths 
(p<0.05), 11% per year for unintentional drug overdose deaths (p<0.05), 15% per year for drug 
overdose deaths involving any opioid (p<0.05), and 16% for unintentional drug overdoses involving 
any opioid (p<0.05). 
Drug overdose deaths involving natural and semi-synthetic opioids, methadone, and synthetic opioids 
other than methadone, United States, 1999–2015 (Figure 2b) 
• The age-adjusted rate of drug overdose deaths involving natural and semi-synthetic opioids increased 
from 1.0 per 100,000 population in 1999 to 3.9 in 2015.
 – Rates for drug overdose deaths involving natural and semi-synthetic opioids increased on average 
12% per year from 1999 to 2010 (p<0.05), then remained stable from 2010 to 2015 (p=0.34). 
• For drug overdoses involving methadone, the rate increased from 0.3 per 100,000 in 1999 to 1.8 in 2006 
(p<0.05), then declined to 1.0 in 2015. 
 – Rates for drug overdose deaths involving methadone increased on average 50% per year from 1999 to 
2002 (p<0.05), 23% per year from 2002 to 2006 (p<0.05), then declined an average of 7% per year from 
2006 to 2015 (p<0.05). 
• For drug overdoses involving synthetic opioids other than methadone, the rate increased from 0.3 per 
100,000 in 1999 to 3.1 in 2015. 
 – Rates for drug overdose deaths involving synthetic opioids other than methadone increased on 
average 18% per year from 1999 to 2006 (p<0.05), remained stable from 2006 to 2013 (p=0.25), then 
increased on average 81% per year from 2013 to 2015 (p<0.05). 
Drug overdose deaths involving heroin, United States, 1999–2015 (Figure 2b)
• The age-adjusted rate of drug overdose deaths involving heroin increased from 0.7 per 100,000 in 1999 
to 4.1 in 2015. 
 – Rates for drug overdose deaths involving heroin remained stable from 1999 to 2005 (p=0.91), 
increased on average 11% per year from 2005 to 2010 (p<0.05), and then increased on average 31% 
per year from 2010 to 2015 (p<0.05). 
Drug overdose deaths involving stimulants, United States, 1999–2015 (Figure 2b)
• The age-adjusted rate of drug overdose deaths involving cocaine increased from 1.4 per 100,000 in 1999 
to 2.1 in 2015. 
 – Rates for drug overdose deaths involving cocaine increased on average 11% per year from 1999 to 
2006 (p<0.05), decreased on average 15% per year from 2006 to 2010 (p<0.05), then increased an 
average of 9% per year from 2010 to 2015 (p<0.05). 
• The age-adjusted rate of drug overdose deaths involving psychostimulants with abuse potential 
increased from 0.2 per 100,000 in 1999 to 1.8 in 2015.
 – Rates for drug overdose deaths involving psychostimulants with abuse potential increased on average 
20% per year from 1999 to 2005 (p<0.05), remained stable from 2005 to 2008 (p=0.40), then increased 
an average of 23% per year from 2008 to 2015 (p<0.05). 
Drug overdose deaths by age category and drug class, United States, 2015 (Figure 2c)
• Among persons ages 15 to 24 years, the rate of drug overdose deaths involving heroin was 3.8 per 
100,000; those involving synthetic opioids other than methadone was 2.3; those involving natural and 
semi-synthetic opioids was 1.6; and those involving methadone was 0.5. 
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• Among persons ages 25 to 34 years, the rate of drug overdose deaths involving heroin was 9.7 per 
100,000; those involving synthetic opioids other than methadone was 6.6; those involving natural and 
semi-synthetic opioids was 5.3; and those involving methadone was 1.7. 
• Among persons ages 35 to 44 years, the rate of drug overdose deaths involving heroin was 7.4 per 
100,000; those involving natural and semi-synthetic opioids was 6.9; those involving synthetic opioids 
other than methadone was 5.6; and those involving methadone was 1.8. 
• Among persons ages 45 to 54 years, the rate of drug overdose deaths involving natural and semi-
synthetic opioids was 8.1 per 100,000; those involving heroin was 5.6; those involving synthetic opioids 
other than methadone was 4.6; and those involving methadone was 2.0. 
• Among persons ages 55 to 64 years, the rate of drug overdose deaths involving natural and semi-
synthetic opioids was 6.4 per 100,000; those involving heroin was 3.4; those involving synthetic opioids 
other than methadone was 2.9; and those involving methadone was 1.6. 
• Rates of drug overdose deaths involving cocaine were 4.3 per 100,000 among 45 to 54 year olds, 3.8 
among 35 to 44 year olds, 3.6 per 100,000 among 25 to 34 year olds, 2.9 among 55 to 64 year olds, 1.0 
among 15 to 24 year olds, and 0.4 among persons 65 and older. 
• Rates of deaths involving psychostimulants with abuse potential were 3.5 per 100,000 among 45 to 54 
year olds, 3.3 among 35 to 44 year olds, 3.0 among 25 to 34 year olds, 2.3 among 55 to 64 year olds, 0.9 
among 15 to 24 year olds, and 0.3 among persons 65 years and older. 
Age-adjusted rates of drug overdose deaths, by state, 2015 (Figure 2e)
• Rates of drug overdose deaths ranged from 6.9 per 100,000 in Nebraska to 41.5 in West Virginia in 2015.
 – States with the highest drug overdose death rates were West Virginia (41.5 per 100,000), New 
Hampshire (34.3), Ohio (29.9), Kentucky (29.9), and Rhode Island (28.2).
 – States with the lowest drug overdose death rates were Nebraska (6.9 per 100,000), South Dakota (8.4), 
North Dakota (8.6), Texas (9.4), and Iowa (10.3).
This report has some notable limitations. In order to comprehensively describe drug use and outcomes in 
the U.S., four distinct data sources were used. While attempted when possible, terminology and definitions 
were not standardized throughout the entire the report. Further, the most recent year of available data 
varied. Collectively, these factors limit comparability of information across sections. Consumers of the 
report should carefully review the technical notes and footnotes to ensure correct interpretation of results, 
especially when comparing information across sections. 
In the mortality section, it should be noted that in approximately 20% of drug overdose deaths, the involved 
drugs were not specified. Although this lack of specificity varies over time and across states, in 2015, 17% of 
drug overdose deaths lacked information about which drugs were involved. Also, records with unknown age 
were not included in estimates by age group, but were included in overall estimates. 
Finally, the report does not address polysubstance use (i.e., the consumption of more than one drug over a 
defined period, simultaneously or at different times for either therapeutic or recreational purposes) nor does 
it explore the need for or receipt of substance use treatment. While these topics are important, they were 
beyond the scope of this report. 
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Opioid-involved overdose deaths, including prescription opioids and illicit opioids, have more than 
quadrupled since 1999. The opioid overdose epidemic, which killed over 33,000 Americans in 2015, 
is comprised of two interrelated waves. The first includes deaths that are due to prescription opioids, 
and the second is due to a rapidly increasing number of deaths due to illicit opioids, such as heroin or 
illicitly manufactured fentanyl (IMF) and fentanyl analogues. Increasingly, fentanyl is being sold as or 
mixed with heroin or cocaine, or being found in counterfeit pills.
CDC plays a vital role in strengthening public health surveillance of opioids at the state and federal levels to 
inform and enhance prevention activities. Through its Overdose Prevention in States effort, CDC maximizes 
its expertise and use of scientific data to inform response efforts. CDC funds multiple programs whose 
activities align with the integration of public health strategies to address the epidemic. Programs include the 
following: 
1 Enhanced State Opioid Overdose Surveillance (ESOOS) – funds 32 states and Washington, DC
a Increase the timelineness of nonfatal opioid overdose reporting in order to serve as an early 
warning system to detect sharp increases (i.e., potential outbreaks) or decreases (i.e., rapidly identify 
successful intervention efforts)
b Increase the timeliness of fatal opioid overdose and associated risk factor reporting
c Disseminate surveillance findings to key stakeholders working to prevent or respond to opioid 
overdoses
2 Prevention for States (PfS) – funds 29 states
a Enhance and maximize prescription drug monitoring programs (PDMPs) 
b Implement community or insurer mechanism or health systems interventions
c Evaluate the impact of prescription opioid-related state policies
3 Data-Driven Prevention Initiative (DDPI) – funds 13 states and Washington, DC
a Improve data collection and analysis around opioid misuse, abuse, and overdose
b Develop strategies that impact behavior driving prescription opioid abuse
c Work with communities to develop more comprehensive opioid overdose prevention programs
Additionally, CDC’s Guideline for Prescribing Opioids for Chronic Pain1, which was released in March 2016, 
serves as a useful resource to providers treating chronic pain for adult patients outside of end-of-life, 
palliative, and active cancer care. Its 12 recommendations allow patients and clinicians to determine risks 
and benefits of opioid therapy and to determine optimal ways to manage pain. These recommendations 
include consideration of nonopioid options that may be more effective at treating chronic pain, such 
as physical therapy. Tools and resources, such as the Opioid Guideline App, which contains a morphine 
milligram equivalent calculator, help disseminate information contained in the guideline and make it easier 
for physicians to make better informed decisions about prescribing. More information can be found at 
https://www.cdc.gov/drugoverdose/prescribing/resources.html. 
CDC also funds cutting-edge research on ways to prevent opioid use disorder and overdose. For example, 
research priorities include identifying factors that increase risk for morbidity and mortality, evaluating the impact 
of state policies and strategies on prescribing behavior and health outcomes, and understanding best practices 
for dissemination and implementation of evidence-based guidelines and recommendations in practice.
 
CDC’s Opioid Overdose Surveillance, Prevention,  
and Research Efforts
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Finally, CDC believes this epidemic requires a partnership across sectors. In addition to the critical 
partnership with states and other federal agencies, CDC has been working side-by-side with law 
enforcement agencies, such as the Drug Enforcement Administration (DEA) and the High Intensity Drug 
Trafficking Areas (HIDTAs). Working together, these sectors can improve surveillance activities and data 
sharing, engage critical stakeholders, provide guidance on prevention and response activities, and evaluate 
the effectiveness of strategies. In particular, collaborations can lead to identification of hot spots to 
strengthen enforcement activities as well as life-saving public health interventions and treatments, such as 
increasing access to naloxone and linkage to treatment for substance use disorder.
Urgent work remains to end the opioid overdose epidemic in the United States. Additional measures are 
now needed to address a diverse and evolving array of drug types. Improving drug overdose surveillance, 
empowering and equipping states with the resources and information they need, improving ways that 
opioids are prescribed through clinical practice guidelines, and forming critical partnerships are at the heart 
of the CDC Injury Center’s work to combat the overdose epidemic.
TECHNICAL 
NOTES
Centers for Disease  
Control and Prevention 
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Prevention and Control
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This report uses the most recent available data from four sources. Information on opioid prescribing 
practices were obtained from QuintilesIMS Health® Transactional Data Warehouse (TDW) and the Total 
Patient Tracker (TPT). Estimated prescribing rates focus on information from 2016, but data are presented 
in tables from 2014-2016, and prescribing trends are also presented during 2006-2016. Substance use and 
misuse information was obtained from the Substance Abuse and Mental Health Services Administration’s 
(SAMHSA) 2014 and 2015 National Survey on Drug Use and Health (NSDUH). Information on hospitalizations 
and emergency department visits for nonfatal, unintentional drug-related poisonings were obtained 
from the Healthcare Cost and Utilization Project’s (HCUP) National Inpatient Sample (NIS) and Nationwide 
Emergency Department Sample (NEDS) 2014 surveys. Mortality rates were obtained from the National Vital 
Statistics System’s (NVSS) 2014 and 2015 mortality file, and trends were presented from 1999-2015. 
Data on demographic characteristics (age, sex, race and ethnicity, and geographic region) were standardized 
across all data sources to the extent possible.
Prescribing Rates
Data Source
Data on opioid prescribing was derived from the QuintilesIMS Health® Transactional Data Warehouse 
(TDW) and the Total Patient Tracker (TPT). TWD provided estimates of the number of opioid prescriptions 
dispensed in the United States, while TPT provided national estimates of the total number of unique patients 
who had at least one opioid prescription dispensed during the year examined. Each were obtained from 
approximately 59,400 retail (non-hospital) pharmacies, representing 90% of all retail prescriptions in the 
United States. A prescription was an initial or refill prescription dispensed at a retail pharmacy in the sample, 
and paid for by commercial insurance, Medicaid, Medicare, or cash or its equivalent. Prescription counts were 
total dispensed prescriptions (TRx), not adjusted for the number of days’ supply.
Opioid prescriptions, including codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, 
oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol and Butrans® (buprenorphine), were 
identified using the National Drug Code. Cough and cold formulations containing opioids were not included. 
Formulations of buprenorphine, an opioid partial agonist primarily used for treatment of opioid use disorder, 
were not included, with the exception of Butrans®, a transdermal buprenorphine formulation used for 
pain. In addition, methadone dispensed through methadone maintenance treatment programs were not 
included in QuintilesIMS TDW data.
Definitions
• Days’ supply: Number of days of supply for the prescription of a specific drug. 
 
• Long-acting (LA) or extended-release (ER) opioids are slower acting medications with a longer 
duration of pain-relieving action, including the following branded and generic drug products:
TECHNICAL NOTES
Data Sources, Definitions and Analysis
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 – Extended release, oral dosage forms containing:
 · Hydromorphone
 · Morphine
 · Oxycodone
 · Oxymorphone
 · Tapentadol
 – Fentanyl and buprenorphine containing transdermal delivery systems
 – Methadone tablets and solutions that are indicated for use as analgesics
• Morphine milligram equivalent (MME): For a comparison of opioids doses, a tool was developed to 
equate the many different opioids into one standard value. This standard value is based on morphine 
and its potency, referred to as morphine milligram equivalent (MME). MME helps determine the potency 
of patients’ opioid doses and is useful if converting from one opioid to another. This measure provides 
the amount of opioids dispensed (i.e., dosage).
 
• Morphine milligram equivalent per day (MME/Day)
 – MME/Day = Strength per Unit X (Number of Units/ Days’ Supply) X MME conversion factor 
 – The “Number of Units” and “Days’ Supply” comes from the prescription. Strength per Unit and MME 
conversion factor is determined by the National Drug Code.
 – Examples: 
 · 10 mg oxycodone tablets X (120 tablets/ 30 days) X 1.5 = 60 MME/day
 · 25 µg/hr. fentanyl patch X (10 patches/ 30 days) X 7.2 = 60 MME/day
• High-dose prescription is defined as prescriptions with a dosage greater than or equal to 90 MME/day.
 – Examples of a dosage at 90 MME/day:
 – 90 mg of hydrocodone (9 tablets of hydrocodone/acetaminophen 10/325)
 – 60 mg of oxycodone (~2 tablets of oxycodone sustained-release 30 mg)
 – ~20 mg of methadone (4 tablets of methadone 5 mg)
• Strength per unit: For combination drugs, “strength” refers to the strength of the controlled substance 
component of the drug per unit specified in UOM (Unit of Measure).
This report provides information on opioid prescribing rates, high-dose prescribing rates, prescribing rates 
by days of supply (≥30 days and <30 days), morphine milligram equivalents (MME) per person, average daily 
MME per prescription, and average days of supply per prescription. 
Statistical Analysis
Annual opioid prescribing rates were calculated by dividing the total number of opioid prescriptions 
dispensed in a given year, or state, as appropriate, by the census population each year. All rates are per 100 
persons. 
Annual resident population denominator estimates were obtained from the Population Estimates Program, 
U.S. Census Bureau. For population data, 2000–2010 Intercensal Estimates of the Resident Population 
for Counties and States were used for 2006–2010 rate calculations; 2010–2016 Postcensal Estimates of 
the Resident Population for Counties and National were used for 2011–2016.
Temporal trends of national opioid prescribing rates and amounts of opioids prescribed from 2006 to 2016 
were evaluated by applying joinpoint regression mothodology.2 This modeling approach simultaneously 
identified statistically significant trends as well as shifts in trends that occur within a time series. A 
maximum of 2 joinpoints was allowed, and the permutation method was used for model selection. The 
most parsimonious models were selected to report the estimated annual percent change (APC) for each 
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time segment detected and the average annual percent change (AAPC) for the full study period. The terms 
increasing or decreasing were used to describe the trend when APC for each time segment was statistically 
significantly different from 0 (p<0.05); otherwise, level was used. Year categories presented in Table 1d 
represented year groupings as determined by joinpoint regression. 
Illicit Drug Use, Prescription Drug Misuse, and Substance Use Disorder
Data Source
The National Survey on Drug Use and Health (NSDUH) is an annual face-to-face household survey 
administered by the Substance Abuse and Mental Health Services Administration.3 NSDUH includes 
questions about substance use behavior, substance use initiation, substance use disorders, substance use 
treatment, and mental health. NSDUH collects data from non-institutionalized persons, aged 12 years and 
older. Non-institutionalized persons include residents living in some group settings (e.g., shelters, boarding 
houses, college dormitories). NSDUH excludes persons with no fixed address (e.g., active duty military 
personnel, persons in jails, persons living in nursing homes, homeless persons not living in shelters).
Sampling and Data Collection
NSDUH collects data using a state-based, multistage area probability sample.3 Each state is stratified into 
sampling regions of approximately equal population sizes. Census tracts are selected within sampling 
regions, census block groups are selected within census tracts, area segments are selected within census 
block groups, and dwelling units are selected within area segments. A maximum of two residents per 
dwelling unit, 12 years of age or older, are selected to participate in the interview. Because NSDUH 
collects information from self-reports of substance use behavior, these data might be subject to under- 
or over reporting biases. NSDUH employs various methods to minimize these potential biases, assuring 
confidentiality of responses and using computer-assisted self-interviewing to maintain privacy. NSDUH data 
reflect prevalence estimates for the entire U.S. non-institutionalized population, accounting for the survey’s 
complex sample design.
Modifications to the Prescription Drug Questions in the 2015 NSDUH
Distinct from prior years, the 2015 NSDUH changed the framing of specific questions from “nonmedical 
use” to “misuse” of prescription drugs.4 In addition, the phrasing of these questions was changed from “for 
the experience or feeling it caused” to “in any way that a doctor did not direct you to use them.” The time 
frame accounted for in questions about prescription drugs also was modified, including past year misuse 
instead of lifetime misuse. A new set of questions was included in the 2015 NSDUH to acquire self-reported 
data for any past year prescription drug use, in addition to misuse. Additionally, methamphetamine use was 
removed from the broader category of prescription stimulants, creating a distinct set of questions focused 
on methamphetamine. Although the aim of these changes was to improve measurement validity, data 
from prior years are not comparable with data gathered using the new and revised questions included in 
the 2015 NSDUH. 
Definitions
This report provides NSDUH prevalence estimates of misuse and overall use (including use as directed 
by a doctor and misuse) for the following prescription drug categories, together referred to by NSDUH as 
“prescription psychotherapeutics”: 
• Prescription pain relievers include opioids (e.g., oxycodone, hydrocodone).
• Prescription tranquilizers include drugs intended to reduce anxiety, specifically benzodiazepines (e.g., 
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alprazolam; lorazepam), or to quell muscle spasms, specifically muscle relaxants (e.g., carisoprodol). 
• Prescription stimulants include drugs prescribed for treatment of attention-deficit hyperactivity 
disorder (e.g., dextroamphetamine, methylphenidate) or obesity (e.g., benzphetamine; phentermine).
• Prescription sedatives include drugs that are intended to manage sleep disorders, such as zolpidem, 
eszopicione, zaleplon, benzodiazepine sedatives (e.g., temazepam, triazolam), and barbiturates (e.g., 
butabarbital, secobarbital).
This report also provides NSDUH prevalence estimates of use for the following illicit substances: 
• Heroin
• Cocaine
• Methamphetamine
In specific tables in this report, estimates are provided for the combination of illicit drug use and 
prescription drug misuse. NSDUH defines a broad category of “illicit drug use” to include the misuse of 
prescription drugs and the use of marijuana, cocaine (including crack), heroin, hallucinogens, inhalants, 
or methamphetamine. This report avoids defining use of illicit drugs and misuse of prescription drugs 
collectively with a label of “illicit drug use” to keep misuse of prescription drugs distinct from the use of 
illicit drugs and to maintain consistency with other data sources included.
Census regions were defined by the following jurisdictions: 
• Northeast: Connecticut, Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont
• Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, 
South Dakota, and Wisconsin
• South: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, 
Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia
• West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, 
Utah, Washington, and Wyoming 
Patient residence was determined according to categories of 2013 National Center for Health Statistics 
Urban-Rural Classification Scheme for Counties.5 Metropolitan and nonmetropolitan categories were 
subdivided into the following categories. 
• Large metropolitan statistical areas (MSAs) (large metropolitan) had a total population of 
 1 million or more. 
• Small metropolitan areas had a total population of:
 – 250,000 to fewer than 1 million.
 – Less than 250,000.
• Nonmetropolitan counties were classified according to the aggregate size of their urban 
population. Nonmetropolitan areas include counties in micropolitan statistical areas and counties 
outside of both metropolitan and micropolitan statistical areas. 
 – These nonmetropolitan categories were categorized as
 · “urbanized” 
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 · “less urbanized” 
 · “completely rural” 
The terms “urbanized,” “less urbanized,” and “completely rural” for counties were not based on the 
relative proportion of the county population in urbanized areas, but rather on the absolute size of 
the population in urbanized areas. For example, some counties classified as “less urbanized” had over 
50 percent of the county population residing in urbanized areas, but this percentage represented fewer 
than 20,000 persons in the county.
Substance Use Disorder was defined as meeting criteria for illicit drug dependence or abuse based on 
definitions found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).6
The prevalence estimates included in this report include the numbers of persons engaging in specific 
behaviors (with numbers in the thousands), the rates of these behaviors per 100 persons, and standard 
errors of the estimated rates. Estimates are suppressed if they were determined to be unreliable due to 
small sample size.
Statistical Analysis 
No statistical analysis were conducted; instead, estimates were obtained from NSDUH’s 2015 published 
report.7 Information on heroin use and dependence stratified by age, race/ethnicity, U.S. census region, 
county type, and urbanization were provided by SAMHSA.
Nonfatal Overdose Hospitalizations and Emergency Department (ED) Visits
Data Sources
Information on medically attended, nonfatal overdose rates were obtained from the Healthcare Cost 
and Utilization Project (HCUP). Drug-related inpatient hospitalizations were obtained from HCUP’s 2014 
National Inpatient Sample (NIS). The NIS uses a stratified systematic random sampling design to produce 
nationally representative estimates of hospital discharges in the United States. It is the largest publicly 
available all-payer database in the U.S. and was conducted in 44 states plus the District of Columbia in 
2014. The sample included approximately 20% of discharges from U.S. community hospitals, excluding 
rehabilitation and long-term acute care facilities. The sample was stratified by the following hospital 
characteristics: U.S. census division, urban or rural location, teaching status, ownership, and bed size. 
Discharge data for emergency department (ED) visits were obtained from the Nationwide Emergency 
Department Sample (NEDS), which is a stratified sample of billing records designed to produce national 
representative estimates of hospital-based ED visits in the United States. In 2014, data were obtained 
from 945 hospitals located in 33 States and the District of Columbia, approximating a 20% stratified 
sample of U.S. hospital-based EDs. The sample was drawn from non-Federal, short-term, general, and 
other specialty hospitals and stratified by the following hospital characteristics: geographic region, 
trauma center designation, urban or rural location, teaching status, and hospital ownership. 
Definitions
The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis injury 
codes were used to classify drug-related poisonings. Principal diagnosis codes and first valid cause of 
external injury or e-codes were used to define the following unintentional drug poisonings: 
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• All drug poisoning included the following codes: 960-979 (poisoning by drugs, medicinal, and 
biological substances) or first listed cause of injury E850-E858 (accidental poisoning by drugs, 
medicinal substances, and biologicals).
• Opioid drug poisoning included: 965.00 (poisoning by opium), 965.01 (poisoning by heroin), 965.02 
(poisoning by methadone), 965.09 (poisoning by other opiates and related narcotics) or E850.0 
(accidental poisoning by heroin), E850.1 (accidental poisoning by methadone), or E850.2 (accidental 
poisoning by other opiates and related narcotics).
• Heroin poisoning was defined by 965.01 (poisoning by heroin) or E850.0 (accidental poisoning by 
heroin).
• Methadone poisoning was defined by 965.02 (poisoning by methadone) or E850.1 (accidental 
poisoning by methadone).
• Other opioids was defined by 965.09 (poisoning by other opiates and related narcotics), 965.00 
(poisoning by opium) or E850.2 (accidental poisoning by other opiates and related narcotics).
• Cocaine was defined by 970.81 or E854.3 (accidental poisoning by central nervous system stimulants) 
or E855.2 (accidental poisoning by local anesthetics convert).
• Methamphetamine was defined by 969.72 or E854.2 (accidental poisoning by psychostimulants).
As poisoning-related hospitalizations and ED visits may involve more than one type of drug, and external 
cause of injury codes were used in addition to principal diagnosis codes, the categories of unintentional, 
drug-related poisoning presented are not mutually exclusive. 
Information about patients’ race and ethnicity was not available for ED visits so it was not included in any 
HCUP analysis. 
Statistical Analysis
Data were weighted to provide national estimates of annual numbers and rates per 100,000 population. 
Rates were based on U.S. population estimates according to sex, age, U.S. census region and 2013 
urbanization status.8,9 Age-adjusted rates were standardized to the U.S. census population estimates for 
2000 by the direct method. Estimates were considered unreliable and not reported if the relative standard 
error was >30% or the standard error = 0. All statistical analysis accounted for the complex sampling 
design and were performed using SAS Version 9.3 (SAS Institute, Cary, North Carolina).
To minimize the possibility of duplicate counting within this section or across other sections of this report, 
some records were excluded. Hospital transfers and hospital admissions that occurred directly from the ED 
were excluded because each would be included in the hospitalization data. In-hospital deaths were excluded 
from the ED visits and hospitalization estimates because these would be included in the mortality section.
Mortality Rates
Data Source
Mortality data were obtained from the Mortality Component of the National Vital Statistics System. Data 
are based on information about underlying and multiple causes of death from death certificates filed in 
the 50 states and the District of Columbia.¹⁰ Drug overdose deaths were analyzed using the multiple cause 
of death query system from CDC WONDER.⁹  
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Definitions
Drug overdose deaths were identified using the International Classification of Diseases, Tenth Revision (ICD-
10), based on the ICD-10 underlying cause-of-death codes X40–44 (unintentional), X60–64 (suicide), X85 
(homicide), or Y10–Y14 (undetermined intent). 
Among deaths with drug overdose as the underlying cause, the type of drugs involved in the deaths were 
indicated by the following ICD-10 multiple cause-of-death codes (i.e., T-codes): 
• Heroin (T40.1)
• Natural/semisynthetic opioids (T40.2), which includes drugs such as hydrocodone and oxycodone
• Methadone (T40.3)
• Synthetic opioids other than methadone (T40.4), which includes drugs such as fentanyl and tramadol
• Deaths involving any opioid (T40.0 (opium), T40.1, T40.2, T40.3, T40.4 and T40.6 (other and unspecified 
narcotics)), which includes drugs such as those listed above, as well as opioids where the type of opioid 
was not specified
• Deaths involving a prescription opioid (T40.2) natural and semi-synthetic opioids and (T40.3) 
methadone
• Cocaine (T40.5)
• Psychostimulants with abuse potential (T43.6), which includes such drugs as methamphetamine, 
and 3,4-methylenedioxy-methamphetamine (MDMA).
As drug overdose deaths may involve more than one type of drug, some deaths are included in the rates 
in more than one subcategory. Therefore, categories of drug overdose deaths presented are not mutually 
exclusive. Additionally, in 2015, approximately 17% of drug overdose deaths do not specify which drugs 
were involved. 
Census regions were defined by the following jurisdictions: 
• Northeast: Connecticut, Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont
• Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, 
South Dakota, and Wisconsin
• South: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, 
Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia
• West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, 
Washington, and Wyoming 
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Decedent’s residence was determined according to categories of 2013 National Center for Health Statistics 
Urban-Rural Classification Scheme for Counties.5
 
• Large central metro: Counties in metropolitan statistical areas (MSAs) of ≥1 million population that 
1) contain the entire population of largest principal city of the MSA, or 2) have their entire population 
contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any 
principal city of the MSA
• Large fringe metro: Counties in MSAs of ≥1 million population that did not qualify as large central 
metro counties
• Medium metro: Counties in MSAs of populations of 250,000–999,999
• Small metro: Counties in MSAs of populations less than 250,000
• Micropolitan (nonmetropolitan counties): Counties in micropolitan statistical areas
• Noncore (nonmetropolitan counties): Nonmetropolitan counties that did not qualify as micropolitan
  
All records with Hispanic origin not stated were not included in estimates by Hispanic origin, 
but were included in the overall estimates. Data for Hispanic origin should be interpreted with 
caution; studies comparing Hispanic origin on death certificates and on census surveys have shown 
inconsistent reporting on Hispanic ethnicity.11 
Statistical Analysis    
Rates were calculated per 100,000 resident population age-adjusted to the 2000 U.S. standard 
population using the vintage year population of the data year. Significance testing for trends over 
time was performed with Joinpoint software from the National Cancer Institute.2 Significance tests 
used a Monte Carlo Permutation method.12 The most parsimonious models were selected to report 
the estimated annual percent change (APC) for each time segment detected that was statistically 
significantly different from 0 (p<0.05); otherwise, the terms level or stable was used.
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TABLE 1A Annual national estimates of total number and rateª for patients who had at least one prescription filled for opioids by age and gender — United States, 2014 – 2016
Age Group (Year) Gender
2014  2015  2016
Number Rate  Number Rate  Number Rate
All ages
Total 65,816,625 20.7 64,950,261 20.2 61,862,364 19.1
 Male 27,715,340 17.7 27,366,942 17.3 26,066,116 16.4
 Female 38,101,284 23.6  37,583,319 23.1  35,796,248 21.8
0 - 14
Total 1,558,274 2.6 1,243,200 2.0 1,235,397 2.0
 Male 820,554 2.6 660,444 2.1 650,608 2.1
 Female 737,720 2.5 582,756 2.0 584,789 2.0
15 - 19
Total 2,700,180 12.8 2,575,134 12.2 2,456,537 11.6
 Male 1,192,243 11.1 1,136,272 10.5 1,084,518 10.0
 Female 1,507,937 14.7 1,438,862 14.0 1,372,019 13.3
20 - 24
Total 3,987,865 17.4 3,761,297 16.6 3,388,088 15.1
 Male 1,519,718 13.0 1,433,424 12.3 1,284,936 11.2
 Female 2,468,147 22.1 2,327,873 21.1 2,103,152 19.3
25 - 34
Total 9,831,819 22.6 9,599,848 21.8 8,872,198 19.9
 Male 3,741,093 17.1 3,657,012 16.4 3,350,037 14.8
 Female 6,090,726 28.3 5,942,836 27.3 5,522,161 25.0
35 - 44
Total 9,994,970 24.7 9,806,536 24.2 9,169,202 22.7
 Male 4,167,350 20.7 4,088,681 20.3 3,801,843 18.9
 Female 5,827,620 28.7 5,717,855 28.1 5,367,359 26.4
45 - 54
Total 11,832,805 27.3 11,596,348 26.9 10,824,755 25.3
 Male 5,196,648 24.3 5,083,190 23.9 4,730,762 22.4
 Female 6,636,158 30.2 6,513,158 29.8 6,093,993 28.1
55 - 64
Total 11,778,335 29.4 12,008,466 29.4 11,677,591 28.2
 Male 5,326,170 27.6 5,435,716 27.6 5,296,001 26.5
 Female 6,452,165 31.1 6,572,749 31.1 6,381,590 29.7
 ≥ 65
Total 14,132,376 30.6 14,359,433 30.1 14,238,597 28.9
 Male 5,751,565 28.3 5,872,203 27.9 5,867,411 26.9
 Female 8,380,811 32.4  8,487,230 31.8  8,371,185 30.5
Source: QuintilesIMS® Total Patient Tracker, 2016 Enhanced.
a Rate per 100 persons adjusted to the U.S. census population.
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TABLE 1B National total number and rateª of opioid prescriptions (Rx) and morphine milligram equivalent (MME) dispensed per 100 persons annually — United States, 2014 – 2016
Source: QuintilesIMS® Transactional Data Warehouse.
Abbreviation: MME, morphine milligram equivalents; Rx, prescription.
a Rate per 100 persons adjusted to the U.S. census population. 
b LA/ER represents opioids that are long acting (LA) or extended release (ER).
Prescribing Opioids
2014  2015 2016
Rx Number Ratea  Rx Number Rate Rx Number Rate
U. S. Census population 318,563,456  320,896,618  323,127,513  
Total patients who had opioid Rx filled 65,816,624  20.7 64,950,261 20.2 61,862,364  19.1 
Rx       
All opioids 240,993,021 75.6 226,819,924 70.6 214,881,622 66.5
LA/ER opioidsb 21,962,468 6.9 21,460,029 6.7 20,394,389 6.3
Days of supply per Rx       
< 30 days 150,436,127 47.2 136,405,883 42.5 126,546,618 39.2
≥ 30 days 90,556,893 28.4 90,414,041 28.2 88,335,004 27.3
Average opioid Rx per patient 3.7  3.5  3.5  
Average days of supply per Rx 17.2  17.7  18.1  
MME       
Total MME 215,925,435,233  205,835,493,929  193,655,422,929  
MME per capita 677.8  641.4  599.3  
Average MME per Rx 896.0  907.5  901.2  
Average daily MME per Rx 48.9  48.1  47.1  
Daily dosage per Rx       
< 50 MME 175,598,424 55.1 165,655,722 51.6 158,045,552 48.9
 ≥ 50 but < 90 MME 42,778,329 13.4 39,740,347 12.4 37,087,169 11.5
 ≥ 90 MME (high-dose) 22,616,268 7.1  21,423,855 6.7 19,748,901 6.1
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TABLE 1C  Ratesª of opioid prescriptions dispensed per 100 persons by dosage, type, and state — United States, 2014 - 2016
Source: QuintilesIMS® Transactional Data Warehouse.
a Rate per 100 persons adjusted to the U.S. census population. 
b MME = morphine milligram equivalents. 
c LA/ER represents opioids that are long acting (LA) or extended release (ER).
State
2014 2015 2016
Opioid Type
Daily Dosage Per Rx 
(MME b/Day) Opioid Type
Daily Dosage Per Rx 
(MME/Day) Opioid Type
Daily Dosage Per Rx 
(MME/Day)
All LA/ER c  < 50 50 but 90  ≥ 90 All LA/ER  < 50 50 but 90  ≥ 90 All LA/ER  < 50 50 but 90  ≥ 90 
Alabama 135.3 10.8 109.3 15.4 10.5 125.1 10.4 100.1  15.2 9.8  121.0  9.9 97.5 14.7 8.8
Alaska 62.7 8.1 37.5 15.4 9.8 60.8 8.3 35.5  15.5 9.8  58.9  8.1 34.8 14.7 9.5
Arizona 79.8 9.3 52.2 16.4 11.2 75.6 9.1 49.3  15.7 10.6  70.2  8.5 46.2 14.4 9.6
Arkansas 123.2 7.7 94.0 19.7 9.5 117.2 7.9 89.6  18.3 9.3  114.6  7.9 89.4 16.7 8.5
California 52.9 4.8 38.6 9.4 4.9 47.9 4.5 35.2  8.1 4.6  44.8  4.1 33.4 7.3 4.1
Colorado 69.6 7.2 45.9 16.4 7.4 65.2 7.1 45.2  13.6 6.5  59.8  6.5 41.7 12.5 5.6
Connecticut 66.1 7.7 42.4 14.7 9.0 62.4 7.3 40.1  14.2 8.1  55.9  6.6 36.4 12.3 7.2
Delaware 91.1 14.4 55.0 19.6 16.5 84.5 13.2 55.0  16.2 13.3  79.2  12.7 52.1 15.1 12.0
District of Columbia 40.1 2.9 33.3 4.2 2.6 35.8 2.6 29.9  3.9 2.0  32.5  2.2 27.4 3.4 1.7
Florida 71.5 7.8 50.9 12.5 8.1 67.2 7.4 47.6  12.4 7.2  66.6  7.4 47.0 12.4 7.2
Georgia 83.8 6.2 65.2 12.3 6.3 79.5 6.0 61.2  12.2 6.1  77.8  5.9 59.8 12.1 6.0
Hawaii 47.8 5.5 32.8 8.7 6.3 44.5 5.0 30.6  8.2 5.7  41.9  4.7 29.4 7.3 5.2
Idaho 87.5 9.5 56.1 21.7 9.7 82.0 9.3 53.0  19.8 9.1  77.6  8.8 50.9 18.5 8.3
Illinois 62.3 4.2 47.9 10.8 3.6 59.1 4.2 46.4  9.2 3.5  56.8  4.1 45.2 8.3 3.3
Indiana 96.7 8.6 73.9 14.9 8.0 89.2 7.9 68.2  13.6 7.4  83.9  7.3 64.6 12.5 6.8
Iowa 72.3 6.1 55.8 11.5 5.1 68.6 6.2 52.5  11.0 5.1  64.0  5.8 49.5 9.8 4.6
Kansas 86.6 8.0 59.1 18.9 8.5 80.7 8.0 54.4  17.6 8.7  76.9  7.6 52.3 16.4 8.1
Kentucky 109.9 7.5 84.2 18.0 7.7 102.6 7.1 78.8  16.9 7.0  97.2  6.6 75.3 15.5 6.4
Louisiana 108.9 6.2 85.3 17.3 6.2 100.4 5.9 78.7  16.1 5.7  98.1  5.9 76.7 15.2 6.2
Maine 82.4 11.2 55.5 14.9 12.0 76.5 11.0 50.2  14.6 11.7  66.9  10.3 44.9 12.2 9.9
Maryland 67.7 8.2 45.0 14.2 8.5 63.1 8.1 41.5  13.7 7.9  58.7  7.8 38.7 12.5 7.6
Massachusetts 59.7 6.0 40.9 12.7 6.0 54.1 5.7 37.8  10.8 5.5  47.1  5.2 33.4 9.1 4.6
Michigan 98.0 8.4 78.5 11.8 7.7 90.5 8.3 72.3  10.7 7.5  84.9  7.8 68.4 9.8 6.7
Minnesota 56.7 5.6 40.8 11.5 4.3 52.2 5.4 37.0  11.2 4.0  46.9  4.9 33.5 9.8 3.6
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State
2014 2015 2016
Opioid Type
Daily Dosage Per Rx 
(MME b/Day) Opioid Type
Daily Dosage Per Rx (MME/
Day) Opioid Type
Daily Dosage Per Rx (MME/
Day)
All LA/ER c  < 50 50 but 90  ≥ 90 All LA/ER  < 50 50 but 90  ≥ 90 All LA/ER  < 50 50 but 90  ≥ 90 
Mississippi 116.3 7.1 93.6 16.2 6.5 111.0 7.1 90.2  14.5 6.3  105.6  7.0 86.6 13.0 6.0
Missouri 90.8 7.2 65.8 17.3 7.7 84.6 7.2 60.7  16.2 7.7  80.4  7.0 58.1 14.9 7.3
Montana 80.1 9.5 53.8 16.7 9.6 73.4 9.0 49.4  15.0 9.0  69.8  8.1 48.3 13.8 7.7
Nebraska 70.2 6.2 51.5 13.4 5.3 65.5 6.1 48.2  12.2 5.1  62.8  5.9 46.5 11.4 4.9
Nevada 90.3 9.3 57.9 20.5 12.0 85.6 9.2 55.3  19.0 11.3  80.7  8.7 53.0 17.7 10.0
New Hampshire 79.6 11.4 48.8 18.4 12.4 74.8 10.8 45.7  17.4 11.7  64.3  9.7 39.9 14.7 9.7
New Jersey 57.3 6.7 37.1 11.2 8.9 56.1 6.6 36.9  10.8 8.5  52.6  6.3 34.5 10.3 7.8
New Mexico 71.6 6.6 50.7 13.8 7.1 70.0 6.3 50.0  13.0 7.0  65.1  5.6 47.2 11.9 6.0
New York 44.0 4.9 31.0 7.3 5.7 45.2 5.0 32.0  7.6 5.7  42.7  4.8 30.1 7.3 5.3
North Carolina 93.8 9.0 66.5 18.4 8.9 88.4 8.8 61.9  18.0 8.6  82.5  8.4 57.8 16.9 7.8
North Dakota 58.1 6.8 41.8 11.6 4.8 53.0 6.4 38.7  10.2 4.2  47.8  5.7 35.7 8.5 3.6
Ohio 89.5 7.0 68.3 14.7 6.6 82.7 6.5 62.8  14.0 5.9  75.3  5.9 57.4 12.7 5.2
Oklahoma 111.0 10.8 75.7 23.7 11.6 104.5 10.9 72.0  21.7 10.9  97.9  10.4 68.0 20.3 9.5
Oregon 92.0 10.6 61.2 20.0 10.8 84.3 9.7 56.0  18.7 9.5  76.3  8.5 51.7 16.8 7.9
Pennsylvania 79.9 8.4 56.6 13.9 9.4 75.6 8.2 53.5  13.2 8.9  69.5  7.7 49.3 12.1 8.1
Rhode Island 72.8 6.4 53.8 12.3 6.7 65.8 6.1 48.8  10.5 6.5  60.3  5.6 44.9 9.6 5.9
South Carolina 101.3 7.7 74.5 18.7 8.1 95.1 7.5 69.5  17.6 8.0  89.4  7.2 65.6 16.2 7.6
South Dakota 61.8 6.1 45.5 11.0 5.2 59.1 6.1 43.4  10.6 5.1  54.8  5.7 41.1 9.2 4.5
Tennessee 121.4 13.0 83.6 24.4 13.4 114.9 12.1 78.8  24.6 11.5  107.5  11.0 74.2 23.5 9.8
Texas 67.1 3.9 53.5 10.4 3.2 59.9 3.9 49.8  7.0 3.1  57.6  3.8 47.9 6.7 3.0
Utah 78.9 8.1 49.1 18.7 11.2 74.5 8.1 46.0  17.8 10.7  70.4  7.8 44.2 16.2 10.1
Vermont 50.4 7.3 33.9 9.3 7.2 60.1 9.2 39.4  11.9 8.8  58.6  9.3 38.8 10.9 8.9
Virginia 73.6 6.4 53.5 12.9 7.1 68.2 6.2 49.2  12.3 6.7  63.4  5.8 46.2 11.0 6.2
Washington 74.3 8.1 50.3 16.4 7.7 69.8 7.8 47.0  15.7 7.2  64.9  7.1 44.1 14.4 6.3
West Virginia 126.4 8.6 99.1 16.7 10.7 111.5 8.3 87.2  14.6 9.7  96.0  7.5 75.7 12.3 8.0
Wisconsin 71.9 8.5 49.9 14.0 8.0 67.6 8.2 46.2  13.7 7.7  62.2  7.5 43.1 12.4 6.6
Wyoming 80.9 8.7 54.1 18.0 8.8 75.4 8.4 49.9  16.7 8.8  71.1  8.1 47.6 15.3 8.2
TABLE 1C  Rates
a of opioid prescriptions dispensed per 100 persons by dosage, type, and state 
— United States, 2014 - 2016
Source: QuintilesIMS® Transactional Data Warehouse.
a Rate per 100 persons adjusted to the U.S. census population. 
b MME = morphine milligram equivalents. 
c LA/ER represents opioids that are long acting (LA) or extended release (ER).
CONTINUED
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TABLE 1D Trend analysis of opioid prescribing — United States, 2006-2016
Source: QuintilesIMS® Transactional Data Warehouse.
Abbreviation: APC, annual percent change; MME, morphine milligram equivalents; Rx, prescription.
a Rate per 100 persons adjusted to the U.S. census population.
b Year category presented in each trend represent year groupings as determined by joinpoint regression.
c Indicates that the Annual Percent Change (APC) was significantly different from zero at the alpha = 0.05 level.
d High-dose prescriptions were defined as opioid prescriptions resulting in a daily dosage of ≥ 90 MME.
Opioid prescribing 
2006 2016
Average APC 
(95% CI)
Trend 1 Trend 2 Trend 3
Prescribing Rate 
per 100 personsa Yearsb APC (95% CI) Years APC (95% CI) Years APC (95% CI)
All opioid Rx 72.4 66.5 -0.8 (-1.1 to -0.4) 2006-2008 4.1 (2.8 to 5.4)c 2008-2012 1.1 (0.5 to 1.7)c 2012-2016 -4.9 (-5.3 to -4.5)c
High-dosage Rx d 11.5 6.1 -6.6 (-7.4 to -5.8) 2006-2009 0 (-2.5 to 2.5) 2009-2016 -9.3 ( -10 to -8.5)c
Days of supply ≥ 30 17.6 27.3 4.3 (3.8 to 4.9) 2006-2010 9.9 (9.2 to 10.5)c 2010-2013 2.9 (1.3 to 4.6)c 2013-2016 -1.3 (-2.1 to -0.5)c
Days of supply < 30 54.7 39.2 -3.2 (-3.6 to -2.8) 2006-2008 1.3 ( -0.1 to 2.7) 2008-2012 -1.2 (-1.9 to -0.5)c 2012-2016 -7.3 (-7.7 to -6.8)c
Number
Average daily MME 
per Rx
59.7 47.1 -2.3 (-2.4 to -2.3) 2006-2010 -1 (-1 to -0.9)c 2010-2013 -4.7 ( -4.8 to -4.5)c 2013-2016 -1.7 (-1.8 to -1.7)c
Average days of 
supply per Rx
13.3 18.1 3.1 (3 to 3.3) 2006-2008 4.4 (4 to 4.8)c 2008-2011 3.4 (3 to 3.7)c 2011-2016 2.5 (2.4 to 2.6)c
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TABLE 2A Self-reported prevalence of illicit drug use in past month, persons 12+ years old, heroin and cocaine: Numbers in Thousands — United States, 2014a
 
Socio-demographic Characteristic
Heroin Cocaine
Numberb Ratec SE  Number Rate SE
All 435 0.2 0.02 1530 0.6 0.04
Sex     
Male 284 0.2 0.04 991 0.8 0.07
Female 151 0.1 0.02 539 0.4 0.04
Age (in years)     
12-17 16 0.1 0.02 39 0.2 0.04
18-25 82 0.2 0.05 473 1.4 0.11
≥ 26 337 0.2 0.03 1,018 0.5 0.05
26-34 172 0.5 0.09 376 1.0 0.14
≥ 35 165 0.1 0.02 642 0.4 0.05
35-39 28 0.1 0.08 164 0.8 0.19
40-44 32 0.2 0.08 105 0.5 0.14
≥ 45 105 0.1 0.03 NA NA NA
45-49 NA NA NA 119 0.6 0.13
50-54 NA NA NA 194 0.8 0.23
55-59 NA NA NA 40 0.2 0.08
60-64 NA NA NA 17 0.1 0.08
≥ 65 NA NA NA 3 0.0 0.00
Race and Hispanic origin     
White, non-Hispanic 270 0.2 0.02 938 0.6 0.05
Black, non-Hispanic 108 0.3 0.10 190 0.6 0.12
Hispanic 43 0.1 0.04 281 0.7 0.11
U.S. Census region of residence     
Northeast 152 0.3 0.07 393 0.8 0.11
Midwest 92 0.2 0.05 238 0.4 0.07
South 109 0.1 0.02 440 0.4 0.06
West 82 0.1 0.04 459 0.7 0.10
County Typed     
Large metropolitan 301 0.2 0.03 1008 0.7 0.06
Small metropolitan 121 0.2 0.03 436 0.6 0.07
250K -- 1 Million Population 91 0.2 0.04 314 0.6 0.09
< 250K Population 29 0.1 0.05 122 0.5 0.11
Non-metropolitan 14 0.0 0.02 87 0.2 0.05
Urbanized 4 0.0 0.02 36 0.2 0.08
Less Urbanized 10 0.1 0.03 39 0.2 0.07
Completely Rural — — —  11 0.3 0.16
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental 
Health Services Administration, Rockville, MD.
NA = data not available
a Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do not 
represent an absence of persons displaying a particular characteristic.
b Numbers in thousands of individuals.
c Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
d Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
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TABLE 2B Self-reported prevalence of illicit drug use and prescription drug misusea in past month, persons 12+ years old: Numbers in Thousands — United States, 2015b
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey 
on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.
— Low precision, no estimate reported; NA = data not available
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including 
use without a prescription of one’s own medication; use in greater amounts, more often, 
or longer than told to take a drug; or use in any other way not directed by a doctor. 
Prescription drugs do not include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are 
rounded to the nearest thousand. Because of this rounding, some prevalence estimates 
Socio-demographic 
Characteristic
All Illicit Drug Usec 
and Prescription Drug 
Misusea
Prescription Pain 
Relievers
Prescription  
Tranquilizers
Prescription 
Stimulants
Prescription 
Sedatives
Heroin Cocaine Methamphetamine
Numberd Ratee SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All 27,080 10.1 0.17 3,775 1.4 0.06 1,874 0.7 0.04 1,653 0.6 0.04 446 0.2 0.02 329 0.1 0.02 1,876 0.7 0.05 897 0.3 0.03
Sex
Male 16,164 12.5 0.27 2,110 1.6 0.10 974 0.8 0.06 877 0.7 0.05 153 0.1 0.02 238 0.2 0.03 1,234 1.0 0.08 631 0.5 0.06
Female 10,915 7.9 0.19 1,665 1.2 0.07 900 0.7 0.05 776 0.6 0.05 293 0.2 0.03 91 0.1 0.01 641 0.5 0.05 266 0.2 0.03
Age (in years)
12-17 2,193 8.8 0.27 276 1.1 0.11 162 0.7 0.09 117 0.5 0.07 21 0.1 0.03 5 0.0 0.01 53 0.2 0.05 13 0.1 0.02
18-25 7,797 22.3 0.42 829 2.4 0.13 582 1.7 0.13 757 2.2 0.15 86 0.2 0.05 88 0.3 0.05 580 1.7 0.14 128 0.4 0.07
≥ 26 17,090 8.2 0.19 2,670 1.3 0.07 1,130 0.5 0.05 779 0.4 0.04 340 0.2 0.03 236 0.1 0.02 1,243 0.6 0.06 757 0.4 0.04
26-34 5,901 15.4 0.47 820 2.1 0.19 400 1.0 0.13 433 1.1 0.15 115 0.3 0.07 116 0.3 0.06 464 1.2 0.16 174 0.5 0.08
≥ 35 11,188 6.6 0.21 1,850 1.1 0.08 730 0.4 0.05 346 0.2 0.03 224 0.1 0.03 120 0.1 0.02 779 0.5 0.06 582 0.3 0.05
35-39 2,067 10.6 0.60 298 1.5 0.23 158 0.8 0.15 65 0.3 0.11 23 0.1 0.07 43 0.2 0.09 180 0.9 0.20 113 0.6 0.16
40-44 1,714 8.5 0.50 341 1.7 0.26 131 0.7 0.14 65 0.3 0.11 52 0.3 0.10 19 0.0 0.06 135 0.7 0.16 107 0.5 0.15
≥ 45 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 58 0.0 0.02 NA NA NA NA NA NA
45-49 1,790 8.6 0.53 387 1.9 0.26 145 0.7 0.15 82 0.4 0.11 57 0.3 0.09 NA NA NA 70 0.3 0.09 138 0.7 0.18
50-54 1,917 8.3 0.73 281 1.2 0.26 98 0.4 0.15 78 0.3 0.13 23 0.1 0.05 NA NA NA 230 1.0 0.26 120 0.5 0.18
55-59 1,681 8.0 0.73 242 1.1 0.30 47 0.2 0.13 34 0.2 0.10 –– –– –– NA NA NA 102 0.5 0.18 75 0.4 0.14
60-64 1,152 6.2 0.69 182 1.0 0.30 57 0.3 0.15 22 0.1 0.09 8 0.0 0.04 NA NA NA 42 0.2 0.12 10 0.1 0.05
≥ 65 866 1.9 0.30 119 0.3 0.08 93 0.2 0.08 –– –– –– 61 0.1 0.06 NA NA NA 19 0.0 0.04 19 0.0 0.04
Race and Hispanic origin
White, non-Hispanic 17,396 10.2 0.22 2,441 1.4 0.07 1,405 0.8 0.06 1,327 0.8 0.05 345 0.2 0.03 237 0.1 0.02 1,096 0.6 0.05 592 0.3 0.04
Black, non-Hispanic 4,023 12.5 0.56 432 1.3 0.19 136 0.4 0.09 36 0.1 0.03 50 0.2 0.06 33 0.1 0.05 439 1.4 0.25 85 0.3 0.10
Hispanic 3,999 9.2 0.39 688 1.6 0.17 239 0.5 0.09 172 0.4 0.06 41 0.1 0.03 50 0.1 0.04 255 0.6 0.09 157 0.4 0.09
equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 
percent and do not represent an absence of persons displaying a particular characteristic.
c Illicit drug use includes the use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine.
d  Numbers in thousands of individuals.
e Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of 
percentages, rounded to the nearest tenth of a percent.
f Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
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Socio-demographic 
Characteristic
All Illicit Drug Usec 
and Prescription Drug 
Misusea
Prescription Pain 
Relievers
Prescription  
Tranquilizers
Prescription  
Stimulants
Prescription 
Sedatives
Heroin Cocaine Methamphetamine
Numberd Ratee SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
U.S. Census region of residence
Northeast 5,104 10.7 0.39 605 1.3 0.12 312 0.7 0.09 312 0.7 0.09 100 0.2 0.06 109 0.2 0.05 411 0.9 0.12 62 0.1 0.05
Midwest 5,473 9.7 0.32 806 1.4 0.13 330 0.6 0.07 393 0.7 0.08 80 0.1 0.04 65 0.1 0.03 289 0.5 0.08 102 0.2 0.04
South 8,800 8.8 0.28 1,499 1.5 0.10 896 0.9 0.08 645 0.6 0.07 147 0.1 0.03 69 0.1 0.02 720 0.7 0.08 375 0.4 0.06
West 7,703 12.2 0.41 865 1.4 0.13 336 0.5 0.06 302 0.5 0.06 119 0.2 0.05 87 0.1 0.04 456 0.7 0.10 358 0.6 0.10
County Typef
Large metropolitan 15,905 10.7 0.24 1,980 1.3 0.08 955 0.6 0.05 890 0.6 0.05 230 0.2 0.03 188 0.1 0.02 1,208 0.8 0.07 461 0.3 0.05
Small metropolitan 8,071 9.9 0.30 1,246 1.5 0.11 663 0.8 0.07 530 0.6 0.06 136 0.2 0.04 99 0.1 0.03 487 0.6 0.07 276 0.3 0.06
250K -- 1 Million 
Population
5,563 9.9 0.34 731 1.3 0.11 453 0.8 0.10 349 0.6 0.07 107 0.2 0.06 53 0.1 0.03 387 0.7 0.09 167 0.3 0.07
< 250K Population 2,508 9.8 0.60 515 2.0 0.24 210 0.8 0.11 181 0.7 0.14 29 0.1 0.04 45 0.2 0.06 100 0.4 0.09 110 0.4 0.10
Non-metropolitan 3,103 8.4 0.37 549 1.5 0.14 256 0.7 0.10 233 0.6 0.10 80 0.2 0.06 42 0.1 0.04 181 0.5 0.09 160 0.4 0.09
Urbanized 1,568 10.4 0.67 227 1.5 0.19 94 0.6 0.14 127 0.8 0.16 47 0.3 0.11 24 0.2 0.07 98 0.7 0.16 61 0.4 0.15
Less Urbanized 1,266 7.4 0.50 260 1.5 0.20 131 0.8 0.14 102 0.6 0.15 30 0.2 0.08 16 0.1 0.06 79 0.5 0.14 92 0.5 0.14
Completely Rural 269 5.9 0.74 62 1.3 0.47 31 0.7 0.40 4 0.1 0.06 3 0.1 0.07 2 0.1 0.05 3 0.1 0.06 8 0.2 0.10
TABLE 2B Self-reported prevalence of illicit drug use and prescription drug misusea in past month, persons 12+ years old: Numbers in Thousands — United States, 2015b
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey 
on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.
— Low precision, no estimate reported; NA = data not available
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including 
use without a prescription of one’s own medication; use in greater amounts, more often, 
or longer than told to take a drug; or use in any other way not directed by a doctor. 
Prescription drugs do not include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are 
rounded to the nearest thousand. Because of this rounding, some prevalence estimates 
equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 
percent and do not represent an absence of persons displaying a particular characteristic.
c Illicit drug use includes the use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine.
d  Numbers in thousands of individuals.
e Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of 
percentages, rounded to the nearest tenth of a percent.
f Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
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TABLE 2C Self-reported prevalence of illicit drug use in past year, persons 12+ years old, heroin and cocaine: Numbers in Thousands — United States, 2014a
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental 
Health Services Administration, Rockville, MD.
NA = data not available
a Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do not 
represent an absence of persons displaying a particular characteristic.
b  Numbers in thousands of individuals.
c Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
d Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
Socio-demographic Characteristic
Heroin  Cocaine
Numberb Ratec SE  Number Rate SE
All 914 0.3 0.03 4,553 1.7 0.07
Sex     
Male 622 0.5 0.05 2,965 2.3 0.11
Female 292 0.2 0.03 1,588 1.2 0.08
Age (in years)     
12-17 28 0.1 0.03 168 0.7 0.09
18-25 268 0.8 0.09 1,604 4.6 0.23
≥ 26 618 0.3 0.03 2,782 1.4 0.08
26-34 346 0.9 0.13 1,140 3.0 0.23
≥ 35 272 0.2 0.03 1,641 1.0 0.08
35-39 78 0.4 0.11 394 2.0 0.28
40-44 66 0.3 0.10 303 1.5 0.22
≥ 45 127 0.1 0.03 NA NA NA
45-49 NA NA NA 261 1.3 0.22
50-54 NA NA NA 352 1.5 0.31
55-59 NA NA NA 193 0.9 0.24
60-64 NA NA NA 59 0.3 0.17
≥ 65 NA NA NA 79 0.2 0.10
Race and Hispanic origin     
White, non-Hispanic 647 0.4 0.03 2,916 1.7 0.08
Black, non-Hispanic 115 0.4 0.10 565 1.8 0.25
Hispanic 119 0.3 0.07 817 1.9 0.20
U.S. Census region of residence     
Northeast 324 0.7 0.10 1,077 2.3 0.17
Midwest 191 0.3 0.06 739 1.3 0.14
South 253 0.3 0.04 1,444 1.5 0.12
West 145 0.2 0.05 1,292 2.1 0.16
County Typed     
Large metropolitan 541 0.4 0.04 2,902 1.9 0.10
Small metropolitan 326 0.4 0.05 1,352 1.7 0.13
250K -- 1 Million Population 240 0.4 0.06 936 1.7 0.15
< 250K Population 86 0.4 0.11 416 1.8 0.24
Non-metropolitan 47 0.1 0.03 298 0.8 0.09
Urbanized 25 0.2 0.05 135 0.8 0.16
Less Urbanized 21 0.1 0.04 141 0.8 0.12
Completely Rural 1 0.0 0.01  23 0.6 0.24
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Socio-demographic 
Characteristic
All Illicit Drug Use 
and Prescription Drug 
Misuse
Prescription Pain 
Relievers
Prescription 
Tranquilizers
Prescription Stimulants Prescription Sedatives Heroin Cocaine Methamphetamine
Numberd Ratee SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All 47,730 17.8 0.23 12,462 4.7 0.11 6,050 2.3 0.08 5,251 2.0 0.07 1,511 0.6 0.04 828 0.3 0.03 4,828 1.8 0.07 1,713 0.6 0.04
Sex
Male 26,576 20.5 0.35 6,924 5.3 0.17 3,148 2.4 0.12 3,027 2.3 0.10 596 0.5 0.05 548 0.4 0.05 3,069 2.4 0.12 1,166 0.9 0.08
Female 21,154 15.3 0.26 5,538 4.0 0.14 2,903 2.1 0.09 2,224 1.6 0.08 915 0.7 0.07 280 0.2 0.03 1,758 1.3 0.07 547 0.4 0.04
Age (in years)
12-17 4,346 17.5 0.37 969 3.9 0.19 394 1.6 0.13 491 2.0 0.14 102 0.4 0.06 21 0.1 0.03 153 0.6 0.08 40 0.2 0.04
18-25 13,102 37.5 0.49 2,979 8.5 0.26 1,847 5.4 0.22 2,537 7.3 0.27 265 0.8 0.08 217 0.6 0.08 1,876 5.4 0.26 329 0.9 0.10
≥ 26 30,281 14.6 0.26 8,513 4.1 0.14 3,782 1.8 0.09 2,223 1.1 0.06 1,143 0.5 0.05 591 0.3 0.04 2,799 1.3 0.08 1,344 0.6 0.06
26-34 10,174 26.5 0.60 2,818 7.4 0.34 1,342 3.5 0.24 1,316 3.4 0.24 337 0.9 0.12 293 0.8 0.11 1,221 3.2 0.24 406 1.1 0.13
≥ 35 20,107 11.9 0.28 5,696 3.4 0.15 2,440 1.4 0.10 907 0.5 0.05 806 0.5 0.06 298 0.2 0.04 1,579 0.9 0.08 938 0.6 0.06
35-39 3,705 19.0 0.75 1,065 5.5 0.44 455 2.3 0.28 316 1.6 0.25 134 0.7 0.16 61 0.3 0.10 397 2.0 0.30 223 1.1 0.23
40-44 2,964 14.8 0.66 979 4.9 0.43 434 2.2 0.29 143 0.7 0.15 107 0.5 0.15 41 0.2 0.07 273 1.4 0.24 156 0.8 0.17
≥ 45 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 196 0.2 0.04 NA NA NA NA NA NA
45-49 3,051 14.7 0.68 941 4.5 0.38 340 1.6 0.22 147 0.7 0.15 106 0.5 0.13 NA NA NA 172 0.8 0.14 205 1.0 0.21
50-54 3,556 15.4 0.95 874 3.8 0.48 476 2.1 0.37 190 0.8 0.22 111 0.5 0.18 NA NA NA 330 1.4 0.31 198 0.9 0.22
55-59 2,976 14.1 0.93 793 3.8 0.50 299 1.4 0.30 79 0.4 0.16 163 0.8 0.23 NA NA NA 281 1.3 0.35 105 0.5 0.16
60-64 1,888 10.1 0.88 434 2.3 0.41 180 1.0 0.32 22 0.1 0.09 36 0.2 0.12 NA NA NA 80 0.4 0.17 13 0.1 0.06
≥ 65 1,967 4.2 0.41 609 1.3 0.21 256 0.6 0.13 9 0.0 0.02 150 0.3 0.10 NA NA NA 46 0.1 0.05 38 0.1 0.06
Race and Hispanic origin
White, non-Hispanic 30,534 17.9 0.29 8,128 4.8 0.14 4,381 2.6 0.10 4,019 2.4 0.09 1,183 0.7 0.06 526 0.3 0.03 3,090 1.8 0.08 1,173 0.7 0.06
Black, non-Hispanic 6,625 20.7 0.67 1,400 4.4 0.36 484 1.5 0.16 212 0.7 0.09 76 0.2 0.07 128 0.4 0.16 760 2.4 0.32 132 0.4 0.12
Hispanic 7,474 17.2 0.49 2,156 5.0 0.28 877 2.0 0.21 651 1.5 0.13 166 0.4 0.09 146 0.3 0.07 744 1.7 0.16 262 0.6 0.10
TABLE 2D Self-reported prevalence of illicit drug usea and prescription drug misuseb in past year, persons 12+ years old: Numbers in Thousands — United States, 2015c
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey 
on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.
NA = data not available
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including 
use without a prescription of one’s own medication; use in greater amounts, more often, 
or longer than told to take a drug; or use in any other way not directed by a doctor. 
Prescription drugs do not include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are 
rounded to the nearest thousand. Because of this rounding, some prevalence estimates 
equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 
percent and do not represent an absence of persons displaying a particular characteristic.
c Illicit drug use includes the use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine.
d  Numbers in thousands of individuals.
e Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of 
percentages, rounded to the nearest tenth of a percent.
f Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
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TABLE 2D
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey 
on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.
NA = data not available
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including 
use without a prescription of one’s own medication; use in greater amounts, more often, 
or longer than told to take a drug; or use in any other way not directed by a doctor. 
Prescription drugs do not include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are 
rounded to the nearest thousand. Because of this rounding, some prevalence estimates 
Socio-demographic 
Characteristic
All Illicit Drug Use  and 
Prescription Drug 
Misuse
Prescription Pain 
Relievers
Prescription 
Tranquilizers
Prescription Stimulants Prescription Sedatives Heroin Cocaine Methamphetamine
Numberd Ratee SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
U.S. Census region of residence
Northeast 8,914 18.6 0.54 2,007 4.2 0.26 1,099 2.3 0.18 986 2.1 0.15 293 0.6 0.11 232 0.5 0.08 1,057 2.2 0.17 119 0.2 0.07
Midwest 9,530 16.8 0.44 2,487 4.4 0.22 1,064 1.9 0.15 1,260 2.2 0.14 250 0.4 0.06 152 0.3 0.04 816 1.4 0.15 234 0.4 0.06
South 16,096 16.1 0.38 4,653 4.6 0.20 2,567 2.6 0.14 1,965 2.0 0.11 568 0.6 0.07 224 0.2 0.05 1,658 1.7 0.11 632 0.6 0.07
West 13,190 20.9 0.54 3,315 5.3 0.26 1,320 2.1 0.15 1,039 1.6 0.12 399 0.6 0.10 221 0.4 0.07 1,296 2.1 0.16 728 1.2 0.13
County Typef
Large metropolitan 28,398 19.0 0.32 7,021 4.7 0.17 3,281 2.2 0.11 2,991 2.0 0.09 848 0.6 0.06 477 0.3 0.05 3,023 2.0 0.11 796 0.5 0.06
Small metropolitan 14,042 17.2 0.40 3,767 4.6 0.19 1,953 2.4 0.14 1,629 2.0 0.11 469 0.6 0.07 243 0.3 0.04 1,319 1.6 0.10 552 0.7 0.08
250K -- 1 Million 
Population
9,694 17.3 0.47 2,505 4.5 0.21 1,367 2.4 0.17 1,053 1.9 0.13 311 0.6 0.09 148 0.3 0.05 955 1.7 0.12 380 0.7 0.10
< 250K Population 4,348 17.0 0.74 1,261 4.9 0.36 586 2.3 0.25 576 2.2 0.22 158 0.6 0.12 95 0.4 0.09 365 1.4 0.19 171 0.7 0.13
Non-metropolitan 5,290 14.4 0.47 1,674 4.6 0.27 817 2.2 0.21 632 1.7 0.15 193 0.5 0.10 109 0.3 0.06 485 1.3 0.14 365 1.0 0.13
Urbanized 2,504 16.5 0.86 742 4.9 0.40 411 2.7 0.36 349 2.3 0.28 122 0.8 0.19 67 0.4 0.12 263 1.7 0.23 117 0.8 0.19
Less Urbanized 2,292 13.5 0.64 786 4.6 0.45 350 2.1 0.29 250 1.5 0.21 67 0.4 0.12 37 0.2 0.09 185 1.1 0.21 220 1.3 0.22
Completely Rural 494 10.8 1.20 145 3.2 0.59 56 1.2 0.42 32 0.7 0.17 4 0.1 0.07 6 0.1 0.07 37 0.8 0.40 28 0.6 0.25
equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 
percent and do not represent an absence of persons displaying a particular characteristic.
c Illicit drug use includes the use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine.
d  Numbers in thousands of individuals.
e Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of 
percentages, rounded to the nearest tenth of a percent.
f Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
CONTINUED
Self-reported prevalence of illicit drug usea and prescription drug misuseb in past year, persons 12+ years old: Numbers in Thousands — United States, 2015c
CDC National Center for Injury Prevention and Control  |  2017Annual Surveillance Report of Drug-Related Risks and Outcomes  |  United States
50
TABLE 2E Self-reported prevalence of prescription drug use (including misuse
a) in past year, 
persons 12+ years old,  by drug type: Numbers in Thousands, United States, 2015b
Socio-demographic Characteristic
Prescription Pain 
Relievers  
Prescription 
Tranquilizers  Prescription Stimulants  Prescription Sedatives
Numberc Rated SE  Number Rate SE  Number Rate SE  Number Rate SE
All 97,499 36.4 0.32 39,317 14.7 0.23 17,212 6.4 0.13 18,564 6.9 0.16
Sex        
Male 44,017 33.9 0.43 14,624 11.3 0.28 8,461 6.5 0.18 7,219 5.6 0.22
Female 53,482 38.8 0.45 24,693 17.9 0.34 8,751 6.3 0.18 11,345 8.2 0.23
Age (in years)        
12-17 5,650 22.7 0.41 1,069 4.3 0.20 1,820 7.3 0.25 602 2.4 0.15
18-25 12,148 34.8 0.47 4,212 12.1 0.33 4,906 14.1 0.37 1,339 3.8 0.18
≥ 26 79,701 38.3 0.39 34,035 16.4 0.29 10,486 5.0 0.15 16,623 8.0 0.20
Race and Hispanic origin        
White, non-Hispanic 65,958 38.7 0.40 30,271 17.8 0.31 12,815 7.5 0.17 14,192 8.3 0.22
Black, non-Hispanic 12,277 38.3 0.85 2,920 9.1 0.51 1,252 3.9 0.32 1,576 4.9 0.38
Hispanic 13,141 30.2 0.71 4,472 10.3 0.45 2,121 4.9 0.29 1,825 4.2 0.32
U.S. Census region of residence        
Northeast 16,055 33.6 0.68 7,333 15.3 0.54 2,894 6.1 0.31 3,181 6.7 0.35
Midwest 20,347 35.9 0.58 7,796 13.8 0.40 3,758 6.6 0.27 3,446 6.1 0.32
South 37,908 37.8 0.55 16,129 16.1 0.40 7,072 7.1 0.24 7,610 7.6 0.29
West 23,188 36.8 0.71 8,058 12.8 0.50 3,488 5.5 0.28 4,326 6.9 0.33
County Typee        
Large metropolitan 51,813 34.7 0.42 20,702 13.9 0.32 9,546 6.4 0.19 9,863 6.6 0.22
Small metropolitan 31,532 38.6 0.60 12,835 15.7 0.40 5,544 6.8 0.23 6,034 7.4 0.30
250K -- 1 Million Population 21,692 38.7 0.75 9,008 16.1 0.47 3,765 6.7 0.26 4,108 7.3 0.37
< 250K Population 9,840 38.5 0.95 3,827 15.0 0.72 1,779 7.0 0.43 1,926 7.5 0.51
Non-metropolitan 14,154 38.5 0.75 5,780 15.7 0.60 2,122 5.8 0.33 2,667 7.3 0.40
Urbanized 6,218 41.0 1.26 2,444 16.1 0.93 988 6.5 0.57 1,177 7.8 0.65
Less Urbanized 6,245 36.7 1.06 2,610 15.3 0.84 887 5.2 0.46 1,162 6.8 0.53
Completely Rural 1,690 37.0 2.05  726 15.9 1.81  248 5.4 0.99  328 7.2 1.29
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental 
Health Services Administration, Rockville, MD.
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including use without a prescription of one’s own medication; 
use in greater amounts, more often, or longer than told to take a drug; or use in any other way not directed by a doctor. Prescription drugs do not 
include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do not 
represent an absence of persons displaying a particular characteristic.
c  Numbers in thousands of individuals.
d Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
e Use of 2013 Rural-Urban Continuum Codes for the creation of the county type variables.
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TABLE 2F Self-reported prevalence of past year initiation of illicit drug use, persons 12+ years old, heroin, cocaine, and methamphetamine: Numbers in Thousands — United States, 2014 and 2015a
Socio-demographic 
Characteristic
2014 2015
Heroin Cocaine Heroin Cocaine Methamphetamine
Numberb Ratec SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All 212 0.1 0.01 766 0.3 0.02 135 0.1 0.01 968 0.4 0.03 225 0.1 0.01
Age (in years)           
12-17 13 0.1 0.03 117 0.5 0.08 11 0.0 0.02 112 0.5 0.07 24 0.1 0.03
18-25 75 0.2 0.04 501 1.4 0.11 57 0.2 0.04 663 1.9 0.15 91 0.3 0.06
≥ 26 124 0.1 0.02 148 0.1 0.02 68 0.0 0.01 193 0.1 0.02 110 0.1 0.01
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental 
Health Services Administration, Rockville, MD.
a Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do 
not represent an absence of persons displaying a particular characteristic.
b  Numbers in thousands of individuals.
c Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
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TABLE 2G Self-reported prevalence of past year initiation of prescription drug misuse
a, persons 12+ years old, by 
prescription drug type: Numbers in Thousands — United States, 2015b
Socio-demographic 
Characteristic
Prescription Pain Relievers  Prescription Tranquilizers  Prescription Stimulants  Prescription Sedatives
Numberc Rated SE  Number Rate SE  Number Rate SE  Number Rate SE
All 2,126 0.8 0.04 1,437 0.5 0.04 1,260 0.5 0.03 425 0.2 0.02
Sex        
Male 916 0.7 0.05 633 0.5 0.05 631 0.5 0.04 155 0.1 0.03
Female 1,210 0.9 0.06 803 0.6 0.05 629 0.5 0.04 270 0.2 0.04
Age (in years)        
12-17 415 1.7 0.13 210 0.8 0.09 276 1.1 0.11 46 0.2 0.04
18-25 596 1.7 0.12 489 1.4 0.11 600 1.7 0.14 86 0.2 0.04
≥ 26 1,114 0.5 0.05  738 0.4 0.04  384 0.2 0.03  293 0.1 0.03
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental Health 
Services Administration, Rockville, MD.
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including use without a prescription of one’s own medication; 
use in greater amounts, more often, or longer than told to take a drug; or use in any other way not directed by a doctor. Prescription drugs do not 
include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do not 
represent an absence of persons displaying a particular characteristic.
c  Numbers in thousands of individuals.
d Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
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TABLE 2H Self-reported prevalence of substance use disorder
a in past year, persons 12+ years old, heroin and 
cocaine: Numbers in Thousands — United States, 2014b
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health. Substance Abuse and Mental Health 
Services Administration, Rockville, MD.
a Substance Use Disorder is defined as meeting criteria for illicit drug or alcohol dependence or abuse. Dependence or abuse is based on definitions 
found in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are rounded to the nearest thousand. Because of this 
rounding, some prevalence estimates equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 percent and do not 
represent an absence of persons displaying a particular characteristic.
c  Numbers in thousands of individuals.
d Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of percentages, rounded to the nearest tenth of a percent.
Socio-demographic 
Characteristic
Heroin  Cocaine
Numberc Rated SE  Number Rate SE
All 586 0.2 0.02 913 0.3 0.03
Age (in years)     
12-17 18 0.1 0.03 27 0.1 0.03
18-25 168 0.5 0.07 185 0.5 0.07
≥ 26 400 0.2 0.03  702 0.3 0.04
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TABLE 2I Self-reported prevalence of substance use disordera in past year persons 12+ years old, by drug type: Numbers in Thousands — United States, 2015b
Source: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey 
on Drug Use and Health. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.
a Misuse of prescription drugs is defined as use in any way not directed by a doctor, including 
use without a prescription of one’s own medication; use in greater amounts, more often, 
or longer than told to take a drug; or use in any other way not directed by a doctor. 
Prescription drugs do not include over-the-counter drugs.
b Prevalence estimates are rounded to the nearest tenth of a percent, and total estimates are 
rounded to the nearest thousand. Because of this rounding, some prevalence estimates 
Socio-demographic 
Characteristic
All Illicit Drug Usec 
and Prescription Drug 
Misuse
Prescription Pain 
Relievers
Prescription 
Tranquilizers Prescription Stimulants Prescription Sedatives Heroin Cocaine Methamphetamine
Numberd Ratee SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All 7,737 2.9 0.08 2,038 0.8 0.04 688 0.3 0.02 426 0.2 0.02 154 0.1 0.01 591 0.2 0.02 896 0.3 0.03 872 0.3 0.03
Age (in years)
12-17 855 3.4 0.17 122 0.5 0.07 77 0.3 0.06 38 0.2 0.04 26 0.1 0.03 6 0.0 0.01 31 0.1 0.04 22 0.1 0.03
18-25 2,530 7.2 0.26 427 1.2 0.11 234 0.7 0.08 159 0.5 0.06 22 0.1 0.02 155 0.4 0.06 229 0.7 0.08 156 0.4 0.07
equal to 0.0 are displayed. These prevalence estimates are rounded down from < 0.05 
percent and do not represent an absence of persons displaying a particular characteristic.
c Illicit drug use includes the use of marijuana, cocaine (including crack), heroin, 
hallucinogens, inhalants, or methamphetamine.
d  Numbers in thousands of individuals.
e Rates per 100 persons. NSDUH presents these as prevalence estimates in the form of 
percentages, rounded to the nearest tenth of a percent.
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TABLE 3A Estimated numberab and age-adjusted rate per 100,000 population of drug poisoning-related hospitalizations by selected substances — United States, 2014
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c Includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d Includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e Includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf
Poisoning by other 
opioidsg Cocaine poisoningsh
Methamphetamine 
poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All Visits 259,665 79.2 0.56 53,000 15.6 0.18 11,475 3.6 0.09 4,580 1.4 0.05 37,125 10.7 0.14 13,265 4.0 0.13 8,290 2.7 0.07
Sex
Male 114,590 71.2 0.64 25,880 15.7 0.25 8,080 5.0 0.14 2,460 1.5 0.07 15,445 9.2 0.18 8,990 5.5 0.2 5,405 3.5 0.12
Female 145,075 87.0 0.7 27,120 15.4 0.24 3,395 2.1 0.09 2,120 1.2 0.06 21,680 12.1 0.2 4,275 2.6 0.11 2,885 1.9 0.08
Age groups (years)
0-14 7,950 13.0 0.75 560 0.9 0.11 k k k 105 0.2 0.04 435 0.7 0.09 140 0.2 0.05 355 0.6 0.08
15-19 15,645 74.2 2.17 935 4.4 0.35 350 1.7 0.2 65 0.3 0.09 520 2.5 0.26 140 0.7 0.13 470 2.2 0.24
20-24 19,260 84.0 1.74 3,600 15.7 0.63 2,205 9.6 0.49 180 0.8 0.13 1,230 5.4 0.35 445 1.9 0.2 1,030 4.5 0.34
25-34 42,725 98.1 1.74 8,755 20.1 0.59 4,260 9.8 0.41 750 1.7 0.14 3,790 8.7 0.35 1,850 4.2 0.25 2,700 6.2 0.31
35-44 39,420 97.3 1.75 6,970 17.2 0.54 1,730 4.3 0.26 740 1.8 0.16 4,510 11.1 0.4 2,350 5.8 0.4 1,700 4.2 0.25
45-54 52,360 120.5 2.03 10,860 25.0 0.68 1,695 3.9 0.28 1,095 2.5 0.19 8,110 18.7 0.55 4,685 10.8 0.7 1,260 2.9 0.21
55-64 42,085 105.0 1.81 11,585 28.9 0.72 985 2.5 0.2 1,155 2.9 0.2 9,495 23.7 0.65 2,885 7.2 0.57 570 1.4 0.15
≥65 40,220 87.1 1.38 9,735 21.1 0.58 230 0.5 0.08 490 1.1 0.11 9,035 19.6 0.55 770 1.7 0.15 205 0.4 0.07
U.S. Census region of residence
Northeast 47,920 81.7 1.41 10,690 17.8 0.49 3,510 6.2 0.27 990 1.7 0.14 6,240 10.0 0.32 4,410 7.5 0.51 575 1.1 0.1
Midwest 57,800 84.7 1.3 11,250 15.9 0.42 3,345 5.1 0.25 865 1.2 0.1 7,070 9.7 0.29 2,340 3.3 0.21 1,300 2.0 0.14
South 101,450 82.3 0.92 19,610 15.3 0.29 2,900 2.4 0.12 1,575 1.3 0.07 15,170 11.6 0.25 5,325 4.3 0.21 2,925 2.5 0.12
West 52,495 68.0 0.99 11,450 14.4 0.35 1,720 2.2 0.13 1,150 1.4 0.1 8,645 10.8 0.3 1,190 1.5 0.12 3,490 4.7 0.2
f Includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g Includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h Includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 or 
E855.2.
i Includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population. Age-adjusted to the 2000 U.S. standard population 
using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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TABLE 3A Estimated numberab and age-adjusted rate per 100,000 population of drug-poisoning related hospitalizations by selected substances — United States, 2014
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c Includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d Includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e Includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf
Poisoning by other 
opioidsg Cocaine poisoningsh
Methamphetamine 
poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
2013 Urbanization 
Large Central Metropolitan 78,000 77.2 1.26 15,515 14.9 0.36 3,950 3.8 0.17 1,585 1.5 0.09 10,045 9.7 0.27 7,080 6.9 0.35 2,795 2.8 0.14
Large Fringe Metropolitan 58,605 72.3 1.2 12,740 15.3 0.39 3,510 4.7 0.21 910 1.1 0.09 8,350 9.6 0.28 2,290 2.8 0.17 1,490 2.0 0.13
Medium Metropolitan 57,540 85.2 1.78 12,070 17.3 0.5 2,340 3.6 0.2 1,025 1.5 0.12 8,760 12.2 0.39 2,050 3.0 0.18 1,750 2.8 0.17
Small Metropolitan 25,790 87.9 2.38 4,860 15.7 0.66 730 2.6 0.24 400 1.4 0.16 3,745 11.8 0.55 620 2.2 0.22 925 3.4 0.3
Micropolitan 23,375 85.4 1.71 4,595 15.6 0.58 525 2.0 0.21 390 1.3 0.16 3,690 12.3 0.5 575 2.3 0.25 720 2.9 0.25
Not Metropolitan or Micropolitan 14,085 74.0 1.97 2,760 13.5 0.65 250 1.6 0.23 205 1.1 0.19 2,310 10.8 0.58 255 1.4 0.2 460 2.8 0.31
Unknown 2,270 0.0 0 460 0.0 0 170 0.0 0 65 0.0 0 225 0.0 0 395 0.0 0 150 0.0 0
f Includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g Includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h Includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 or 
E855.2.
i Includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population. Age-adjusted to the 2000 U.S. standard population 
using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
CONTINUED
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TABLE 3B Estimated number
ab and age-adjusted rate per 100,000 population of drug-poisoning related emergency department visits by selected substances 
— United States, 2014
a Weighted national estimates from HCUP Nationwide Emergency Department Sample 
(NEDS), 2014, Agency for Healthcare Research and Quality (AHRQ).
b Persons who were hospitalized, died, or transferred to another facility were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf
Poisoning by other 
opioidsg Cocaine poisoningsh
Methamphetamine 
poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All Visits 418,313 133.7 1.95 92,262 28.9 0.99 53,930 17.1 0.84 2,921 0.9 0.04 35,690 11.0 0.21 6,424 2.1 0.1 11,012 3.6 0.1
Sex
 Male 199,999 127.9 2.32 57,655 36.3 1.4 38,035 24.0 1.21 1,554 1.0 0.06 18,242 11.4 0.28 4,462 2.9 0.17 6,752 4.4 0.15
 Female 218,313 139.5 1.8 34,607 21.6 0.64 15,894 10.2 0.51 1,367 0.8 0.06 17,448 10.6 0.23 1,962 1.3 0.07 4,260 2.8 0.1
Age groups (years)
 0-14 70,984 116.2 4.12 2,263 3.7 0.23 k k k 95 0.2 0.03 2,126 3.5 0.22 472 0.8 0.09 2,244 3.7 0.22
 15-19 46,755 221.8 7.19 4,170 19.8 1.16 1,796 8.5 0.79 64 0.3 0.08 2,321 11.0 0.63 226 1.1 0.17 1,318 6.3 0.45
 20-24 48,443 211.3 8.91 16,294 71.1 4.96 12,276 53.5 4.35 231 1.0 0.16 3,848 16.8 0.89 589 2.6 0.23 1,873 8.2 0.58
 25-34 80,785 185.5 9.12 30,478 70.0 5.72 22,411 51.5 4.99 675 1.6 0.16 7,503 17.2 0.9 1,662 3.8 0.39 3,051 7.0 0.43
 35-44 53,233 131.3 5.42 14,410 35.6 2.68 8,703 21.5 2.15 558 1.4 0.16 5,177 12.8 0.68 1,369 3.4 0.38 1,376 3.4 0.27
 45-54 50,116 115.3 4.44 12,328 28.4 1.91 5,869 13.5 1.45 575 1.3 0.15 5,929 13.6 0.61 1,250 2.9 0.41 734 1.7 0.15
 55-64 34,075 85.0 2.73 8,061 20.1 1.01 2,458 6.1 0.62 488 1.2 0.16 5,132 12.8 0.56 703 1.8 0.23 321 0.8 0.1
 ≥65 33,922 73.4 2 4,258 9.2 0.42 375 0.8 0.14 236 0.5 0.07 3,655 7.9 0.37 152 0.3 0.06 95 0.2 0.05
U.S. Census region of residence
 Northeast 83,450 154.0 7.14 27,462 49.9 4.48 20,570 37.7 3.93 585 1.0 0.12 6,356 11.3 0.67 1,105 2.1 0.17 1,125 2.2 0.16
 Midwest 100,900 153.7 4.26 24,944 37.9 2.32 16,162 24.8 1.93 433 0.7 0.09 8,437 12.6 0.52 1,127 1.8 0.16 2,377 3.7 0.21
 South 137,841 117.0 2.66 25,100 20.9 0.96 11,802 9.9 0.75 975 0.8 0.07 12,393 10.2 0.31 3,128 2.7 0.23 3,694 3.2 0.14
 West 96,122 128.5 2.93 14,756 19.0 0.67 5,396 7.0 0.41 929 1.2 0.1 8,504 10.9 0.35 1,063 1.4 0.15 3,816 5.1 0.28
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 
or E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population. Age-adjusted to the 2000 U.S. standard 
population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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TABLE 3B Estimated number
ab and age-adjusted rate per 100,000 population of drug-poisoning related emergency department visits by selected substances 
— United States, 2014
Socio-demographic Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf
Poisoning by other 
opioidsg Cocaine poisoningsh
Methamphetamine 
poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
2013 Urbanization 
 Large Central Metropolitan 104,834 106.5 3.14 22,862 22.2 1.13 13,122 12.7 0.86 1,170 1.1 0.09 8,672 8.5 0.34 2,619 2.6 0.22 3,155 3.1 0.19
 Large Fringe Metropolitan 89,713 117.9 4.63 27,093 35.9 2.87 19,012 25.5 2.54 485 0.6 0.07 7,658 9.8 0.44 1,196 1.6 0.13 1,697 2.3 0.14
 Medium Metropolitan 111,082 170.9 4.96 23,438 35.8 2.05 13,468 20.8 1.67 625 1.0 0.09 9,425 14.1 0.55 1,514 2.4 0.17 2,919 4.6 0.23
 Small Metropolitan 40,317 142.2 5.82 7,143 24.6 2.24 3,330 11.7 1.73 222 0.8 0.12 3,600 12.2 0.71 430 1.5 0.21 1,199 4.3 0.33
 Micropolitan 41,919 161.4 3.42 6,776 26.0 1.4 3,084 12.3 1.14 178 0.7 0.13 3,529 13.0 0.55 316 1.3 0.18 1,069 4.4 0.32
 Not Metropolitan or Micropolitan 26,890 153.1 3.47 3,720 20.5 1.02 975 6.1 0.7 207 1.1 0.18 2,537 13.2 0.66 208 1.3 0.19 804 5.0 0.43
 Unknown 3,557 1,230 0.0 0 938 0.0 0 k k k 269 0.0 0 k k k 168 0.0 0
a Weighted national estimates from HCUP Nationwide Emergency Department Sample 
(NEDS), 2014, Agency for Healthcare Research and Quality (AHRQ).
b Persons who were hospitalized, died, or transferred to another facility were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of 
injury E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 
or E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population. Age-adjusted to the 2000 U.S. standard 
population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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TABLE 3C Estimated numberab and percent of drug-poisoning related hospitalization and emergency department visits by primary payer — United States, 2014
a Weighted national estimates from HCUP National Inpatient Survey (NIS) and Nationwide 
Emergency Department Sample (NEDS), 2014, Agency for Healthcare Research and Quality 
(AHRQ).
b Persons who were hospitalized, died, or transferred to another facility were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf Poisoning by other opioidsg Cocaine poisoningsh Methamphetamine poisoningsi
Hospitalizations ED visits Hospitalizations ED visits Hospitalizations ED visits Hospitalizations ED visits Hospitalizations ED visits Hospitalizations ED visits Hospitalizations ED visits
Total 259,665 418,313 53,000 92,262 11,475 53,930 4,580 2,921 37,125 35,690 13,265 6,424 8,290 11,012
Number % Number % Number % Number % Number % Number % Number % Number % Number % Number % Number % Number % Number % Number %
Payer
Medicare 80,525 31.0 66,835 16.0 20,185 38.1 11,989 13.0 1,135 9.9 3,281 6.1 1,440 31.4 566 19.4 17,645 58.7 8,170 29.0 2,555 19.3 651 10.1 1,030 12.4 625 5.7
Medicaid 78,780 30.3 148,359 35.5 15,610 29.5 33,702 36.5 5,045 44.0 21,612 40.1 1,775 38.8 1,378 47.2 8,875 29.5 10,826 38.5 6,240 47.0 2,428 37.8 3,295 39.7 3,737 33.9
Private 59,630 23.0 114,638 27.4 9,735 18.4 18,730 20.3 2,565 22.4 9,773 18.1 615 13.4 343 11.7 6,580 21.9 8,659 30.8 1,465 11.0 1,044 16.3 1,450 17.5 3,050 27.7
Uninsured 31,735 12.2 68,179 16.3 5,805 11.0 22,676 24.6 2,390 20.8 15,804 29.3 620 13.5 547 18.7 2,830 9.4 6,406 22.8 2,590 19.5 1,927 30.0 2,085 25.2 2,924 26.6
Other 8,495 3.3 19,396 4.6 1,555 2.9 j 320 2.8 j 130 2.8 j 1,105 3.7 1,552 5.5 390 2.9 365 5.7 400 4.8 637 5.8
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 or 
E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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Socio-demographic 
Characteristic
Drug overdose 
deaths, overall
Drug overdose deaths involving: 
Any opioidf
Natural and semi-
synthetic opioidsg Methadoneh
Synthetic opioids other 
than methadonei Prescription opioidsj Heroink Cocainel
Psychostimulants with 
abuse potentialm
Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All  52,404 16.3 0.072  33,091 10.4 0.058  12,727 3.9 0.035  3,301 1.0 0.018  9,580 3.1 0.032 15,281 4.7 0.039  12,989 4.1 0.037  6,784 2.1 0.026  5,716 1.8 0.024
Sex
Male  32,957 20.8 0.116  21,671 13.7 0.095  7,117 4.4 0.054  1,939 1.2 0.028  6,560 4.2 0.053 8,617 5.4 0.059  9,881 6.3 0.064 4,885 3.1 0.045 3,971 2.5 0.041
Female  19,447 11.8 0.087  11,420 7.1 0.067  5,610 3.4 0.046  1,362 0.8 0.023  3,020 1.9 0.035 6,664 4.0 0.05  3,108 2.0 0.037  1,899 1.2 0.028 1,745 1.1 0.027
Age group (years)
0-14  144 0.2 0.02  83 0.1 0.015  48 0.1 0.011  13 --* --*  14 --* --* 61 0.1 0.013 --* --* --* --* --* --*  11 --* --*
15-19  772 3.7 0.132  506 2.4 0.107  136 0.6 0.055  53 0.3 0.034  143 0.7 0.057 184 0.9 0.064  208 1.0 0.068  70 0.3 0.04  82 0.4 0.043
20-24  3,463 15.2 0.259  2,576 11.3 0.223  579 2.5 0.106  148 0.7 0.053  856 3.8 0.129 702 3.1 0.117  1,441 6.3 0.167  372 1.6 0.085  334 1.5 0.08
25-34  11,880 26.9 0.247  8,568 19.4 0.21  2,327 5.3 0.109  735 1.7 0.061  2,896 6.6 0.122 2,906 6.6 0.122  4,292 9.7 0.148  1,571 3.6 0.09  1,307 3.0 0.082
35-44  11,505 28.3 0.264  7,484 18.4 0.213  2,819 6.9 0.131  739 1.8 0.067  2,289 5.6 0.118 3,390 8.4 0.143  3,012 7.4 0.135  1,549 3.8 0.097  1,357 3.3 0.091
45-54  12,974 30.0 0.264  7,595 17.6 0.202  3,479 8.1 0.137  843 2.0 0.067  1,982 4.6 0.103 4,100 9.5 0.148  2,439 5.6 0.114  1,861 4.3 0.1  1,513 3.5 0.09
55-64  8,901 21.8 0.231  5,089 12.4 0.175  2,602 6.4 0.125  642 1.6 0.062  1,167 2.9 0.084 3,101 7.6 0.136  1,407 3.4 0.092  1,166 2.9 0.084  946 2.3 0.075
≥65  2,760 5.8 0.11  1,188 2.5 0.072  736 1.5 0.057  127 0.3 0.024  232 0.5 0.032 835 1.7 0.061  184 0.4 0.028  194 0.4 0.029  164 0.3 0.027
Race and Hispanic originc
White, non-Hispanic  41,720 21.1 0.106  27,056 13.9 0.087  10,774 5.3 0.053  2,725 1.4 0.027  7,995 4.2 0.048 12,894 6.4 0.058 10,050 5.4 0.055  4,225 2.2 0.035  4,324 2.2 0.035
Black, non-Hispanic  5,070 12.2 0.174  2,741 6.6 0.127  878 2.1 0.074  247 0.6 0.038  883 2.1 0.072 1,060 2.6 0.08 1,310 3.1 0.087  1,690 4.0 0.099  316 0.8 0.044
Hispanic  4,117 7.7 0.122  2,507 4.6 0.093  780 1.5 0.053  235 0.5 0.03  524 0.9 0.042 961 1.8 0.059 1,299 2.3 0.065 697 1.3 0.049 725 1.4 0.051
TABLE 4A Number and age-adjusted rates
a of all drug overdose deathsband selected drugs by sex, race and Hispanic originc, Census regiond, urbanizatione, and intent 
— United States, 2015
Source: National Vital Statistics System, Mortality File, CDC WONDER. SE = standard error.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year 
population of the data year. *Rates are suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug 
overdose deaths are identified using underlying cause-of-death codes X40–X44 (unintentional), X60–X64 
(suicide), X85 (homicide), and Y10–Y14 (undetermined). Because deaths might involve more than one 
drug, some deaths are included in more than one category. On death certificates, the specificity of drugs 
involved with deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include 
information on the specific type of drug(s) involved.
c Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death 
certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity.
d Census regions are defined by the following jurisdictions: Region 1: Connecticut, Delaware, Maine, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Region 2: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, 
and Wisconsin; Region 3: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, 
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West 
Virginia; Region 4: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming.
e Categories of 2013 NCHS Urban-Rural Classification Scheme for Counties  
(http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf):  
Large central metro: Counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) 
contain the entire population of largest principal city of the MSA, or 2) have their entire population 
contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal 
city of the MSA; Large fringe metro: Counties in MSAs of ≥1 million population that did not qualify as large 
central metro counties; Medium metro: Counties in MSAs of populations of 250,000–999,999; Small metro: 
Counties in MSAs of populations less than 250,000; Micropolitan (nonmetropolitan counties): counties in 
micropolitan statistical areas; Noncore (nonmetropolitan counties): nonmetropolitan counties that did not 
qualify as micropolitan.
f Drug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic 
opioids (T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4) and other and 
unspecified narcotics (T40.6).
g Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
h Drug overdose deaths, as defined, that involve methadone (T40.3).
i Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
j Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2) and methadone 
(T40.3).
k Drug overdose deaths, as defined, that involve heroin (T40.1).
l Drug overdose deaths, as defined, that involve cocaine (T40.5).
m Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
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TABLE 4A Number and age-adjusted rates
a of all drug overdose deathsband selected drugs by sex, race and 
Hispanic originc, Census regiond, urbanizatione, and intent — United States, 2015
Socio-demographic 
Characteristic
Drug overdose 
deaths, overall
Drug overdose deaths involving: 
Any opioidf
Natural and semi-
synthetic opioidsg Methadoneh
Synthetic opioids other 
than methadonei Prescription opioidsj Heroink Cocainel
Psychostimulants with 
abuse potentialm
Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
U.S. Census region of residenced
Northeast  11,096 19.8 0.192  7,576 13.6 0.16  2,095 3.6 0.081  643 1.1 0.045  3,071 5.6 0.103 2,605 4.5 0.091  3,461 6.3 0.109  1,861 3.3 0.079  274 0.5 0.03
Midwest  11,785 17.8 0.167  8,011 12.2 0.139  2,302 3.4 0.073  673 1.0 0.04  2,548 3.9 0.08 2,848 4.2 0.081  3,959 6.1 0.099  1,680 2.5 0.063  706 1.1 0.043
South  18,613 15.5 0.115  11,747 9.8 0.092  5,374 4.4 0.062  1,228 1.0 0.03  3,303 2.8 0.049 6,282 5.2 0.067  3,722 3.2 0.053  2,564 2.2 0.043  1,724 1.5 0.036
West  10,910 13.9 0.136  5,757 7.4 0.099  2,956 3.8 0.07  757 1.0 0.035  658 0.9 0.034 3,546 4.5 0.077  1,847 2.4 0.056  679 0.9 0.034  3,012 3.9 0.072
2013 Urbanizatione
Large Central 
Metropolitan
 15,325 14.8 0.122  9,679 9.4 0.097  3,438 3.3 0.057  1,069 1.0 0.032  2,509 2.4 0.049 4,276 4.1 0.064  4,496 4.4 0.066  2,786 2.7 0.051  2,003 2.0 0.044
Large Fringe 
Metropolitan
 13,032 16.5 0.147  8,683 11.2 0.122  2,870 3.5 0.067  734 0.9 0.035  2,947 3.9 0.072 3,444 4.2 0.074  3,778 5.0 0.082  1,617 2.1 0.052  909 1.2 0.039
Medium Metropolitan  11,982 18.3 0.171  7,618 11.8 0.138  3,071 4.7 0.086  755 1.2 0.043  2,255 3.5 0.076 3,664 5.6 0.094  2,736 4.3 0.083  1,462 2.3 0.061  1,378 2.1 0.058
Small Metropolitan  4,720 16.8 0.251  2,729 9.9 0.194  1,193 4.2 0.126  265 1.0 0.061  686 2.5 0.1 1,404 5.0 0.136  868 3.2 0.111  419 1.5 0.077  533 2.0 0.087
Micropolitan  4,512 17.5 0.268  2,730 10.8 0.211  1,248 4.8 0.14  281 1.1 0.067  753 3.0 0.113 1,457 5.6 0.151  778 3.2 0.117  360 1.4 0.078  517 2.0 0.091
Noncore  2,833 16.2 0.316  1,652 9.6 0.245  907 5.1 0.177  197 1.2 0.089  430 2.6 0.127 1,036 5.9 0.191  333 2.1 0.116  140 0.9 0.074  376 2.3 0.12
Intent
Unintentional  44,126 13.8 0.067  29,382 9.3 0.055  10,621 3.3 0.033  2,955 0.9 0.017  8,609 2.8 0.03 12,923 4.0 0.036  12,284 3.9 0.036  6,467 2.0 0.026  5,307 1.7 0.023
Undetermined  2,979 0.9 0.017  1,857 0.6 0.013  807 0.3 0.009  237 0.1 0.005  544 0.2 0.007 985 0.3 0.009  586 0.2 0.008  208 0.1 0.005  174 0.05 0.004
Suicide  5,206 1.5 0.022  1,803 0.5 0.013  1,287 0.4 0.010  107 0.02 0.003  415 0.1 0.007 1,359 0.4 0.011  92 0.03 0.004  100 0.03 0.004  216 0.1 0.004
Source: National Vital Statistics System, Mortality File, CDC WONDER. SE = standard error.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year 
population of the data year. *Rates are suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug 
overdose deaths are identified using underlying cause-of-death codes X40–X44 (unintentional), X60–X64 
(suicide), X85 (homicide), and Y10–Y14 (undetermined). Because deaths might involve more than one 
drug, some deaths are included in more than one category. On death certificates, the specificity of drugs 
involved with deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include 
information on the specific type of drug(s) involved.
c Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death 
certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity.
d Census regions are defined by the following jurisdictions: Region 1: Connecticut, Delaware, Maine, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Region 2: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, 
and Wisconsin; Region 3: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, 
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West 
Virginia; Region 4: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming.
e Categories of 2013 NCHS Urban-Rural Classification Scheme for Counties  
(http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf):  
Large central metro: Counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) 
contain the entire population of largest principal city of the MSA, or 2) have their entire population 
contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal 
city of the MSA; Large fringe metro: Counties in MSAs of ≥1 million population that did not qualify as large 
central metro counties; Medium metro: Counties in MSAs of populations of 250,000–999,999; Small metro: 
Counties in MSAs of populations less than 250,000; Micropolitan (nonmetropolitan counties): counties in 
micropolitan statistical areas; Noncore (nonmetropolitan counties): nonmetropolitan counties that did not 
qualify as micropolitan.
f Drug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic 
opioids (T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4) and other and 
unspecified narcotics (T40.6).
g Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
h Drug overdose deaths, as defined, that involve methadone (T40.3).
i Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
j Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2) and methadone 
(T40.3).
k Drug overdose deaths, as defined, that involve heroin (T40.1).
l Drug overdose deaths, as defined, that involve cocaine (T40.5).
m Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
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TABLE 4B Number and age-adjusted rates
a of all drug overdose deathsb and selected drugs by sex, race and Hispanic originc, Census regiond, urbanizatione, and intent 
— United States, 2014
Source: National Vital Statistics System, Mortality File, CDC WONDER. SE = standard error.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year 
population of the data year. *Rates are suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug 
overdose deaths are identified using underlying cause-of-death codes X40–X44 (unintentional), X60–X64 
(suicide), X85 (homicide), and Y10–Y14 (undetermined). Because deaths might involve more than one 
drug, some deaths are included in more than one category. On death certificates, the specificity of of drugs 
involved with deaths varies over time. In 2014, approximately 19% of drug overdose deaths did not include 
information on the specific type of drug(s) involved.
c Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death 
certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity.
d Census regions are defined by the following jurisdictions: Region 1: Connecticut, Delaware, Maine, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Region 2: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, 
and Wisconsin; Region 3: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, 
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West 
Virginia; Region 4: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming.
e Categories of 2013 NCHS Urban-Rural Classification Scheme for Counties  
(http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf):  
Socio-demographic 
Characteristic
Overall drug overdoses
Drug overdose deaths involving: 
Any opioidf
Natural and semi-
synthetic opioidsg Methadoneh
Synthetic opioids other 
than methadonei Prescription opioidsj Heroink Cocainel
Psychostimulants with 
abuse potentialm
Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All  47,055 14.7 0.069  28,647 9.0 0.054  12,159 3.8 0.035  3,400 1.1 0.019  5,544 1.8 0.024 14,838 4.6 0.038  10,574 3.4 0.034  5,415 1.7 0.024  4,298 1.4 0.021
Sex
Male  28,812 18.3 0.109  18,420 11.7 0.088  6,732 4.2 0.052  2,009 1.3 0.029  3,465 2.2 0.038 8,332 5.2 0.058  8,160 5.2 0.059 3,880 2.4 0.04 3,020 1.9 0.036
Female  18,243 11.1 0.084  10,227 6.3 0.064  5,427 3.3 0.046  1,391 0.9 0.024  2,079 1.3 0.028 6,506 3.9 0.05  2,414 1.6 0.032  1,535 1.0 0.026 1,278 0.8 0.023
Age group (years)
0-14  109 0.2 0.017  64 0.1 0.013  42 0.1 0.011  14 --* --*  10 --* --* 55 0.1 0.012  --* --* --*  --* --* --*  11 --* --*
15-19  658 3.1 0.122  416 2.0 0.097  133 0.6 0.055  50 0.2 0.034  70 0.3 0.04 177 0.8 0.063  180 0.9 0.064  35 0.2 0.028  50 0.2 0.034
20-24  3,140 13.7 0.245  2,290 10.0 0.209  593 2.6 0.106  191 0.8 0.06  444 1.9 0.092 754 3.3 0.12  1,272 5.6 0.156  299 1.3 0.075  290 1.3 0.074
25-34  10,055 23.1 0.23  7,028 16.2 0.193  2,115 4.9 0.106  796 1.8 0.065  1,474 3.4 0.088 2,776 6.4 0.121  3,493 8.0 0.136  1,165 2.7 0.078  963 2.2 0.071
35-44  10,134 25.0 0.248  6,338 15.6 0.197  2,644 6.5 0.127  768 1.9 0.068  1,264 3.1 0.088 3,257 8.0 0.141  2,398 5.9 0.121  1,219 3.0 0.086  995 2.5 0.078
45-54  12,263 28.2 0.255  6,987 16.1 0.192  3,488 8.0 0.136  854 2.0 0.067  1,359 3.1 0.085 4,127 9.5 0.148  2,030 4.7 0.104  1,621 3.7 0.093  1,221 2.8 0.08
55-64  8,122 20.3 0.225  4,452 11.1 0.166  2,437 6.1 0.123  629 1.6 0.063  742 1.9 0.068 2,916 7.3 0.135  1,064 2.7 0.081  912 2.3 0.075  668 1.7 0.064
≥65  2,568 5.6 0.11  1,070 2.3 0.071  706 1.5 0.057  98 0.2 0.021  181 0.4 0.029 775 1.7 0.06  136 0.3 0.025  161 0.3 0.027  99 0.2 0.022
Race and Hispanic originc
White, non-Hispanic  37,945 19.0 0.1  23,574 12.0 0.081  10,308 5.0 0.051  2,845 1.4 0.028  4,685 2.4 0.036 12,549 6.2 0.057 8,253 4.4 0.05  3,351 1.7 0.031  3,307 1.7 0.03
Black, non-Hispanic  4,323 10.5 0.162  2,298 5.6 0.118  814 2.0 0.07  256 0.6 0.04  449 1.1 0.052 1,017 2.5 0.078 1,044 2.5 0.079  1,409 3.4 0.092  215 0.5 0.035
Hispanic  3,504 6.7 0.116  2,107 4.0 0.089  727 1.4 0.053  228 0.5 0.031  302 0.6 0.033 906 1.8 0.06 1,049 1.9 0.061 525 1.0 0.045 530 1.0 0.044
Large central metro: Counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) 
contain the entire population of largest principal city of the MSA, or 2) have their entire population 
contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal 
city of the MSA; Large fringe metro: Counties in MSAs of ≥1 million population that did not qualify as large 
central metro counties; Medium metro: Counties in MSAs of populations of 250,000–999,999; Small metro: 
Counties in MSAs of populations less than 250,000; Micropolitan (nonmetropolitan counties): counties in 
micropolitan statistical areas; Noncore (nonmetropolitan counties): nonmetropolitan counties that did not 
qualify as micropolitan.
f Drug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic 
opioids (T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4) and other and 
unspecified narcotics (T40.6).
g Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
h Drug overdose deaths, as defined, that involve methadone (T40.3).
i Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
j Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2) and methadone 
(T40.3).
k Drug overdose deaths, as defined, that involve heroin (T40.1).
l Drug overdose deaths, as defined, that involve cocaine (T40.5).
m Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
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TABLE 4B Number and age-adjusted rates
a of all drug overdose deathsb and selected drugs by sex, race and Hispanic originc, Census regiond, urbanizatione, and intent 
— United States, 2014
Source: National Vital Statistics System, Mortality File, CDC WONDER. SE = standard error.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year 
population of the data year. *Rates are suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug 
overdose deaths are identified using underlying cause-of-death codes X40–X44 (unintentional), X60–X64 
(suicide), X85 (homicide), and Y10–Y14 (undetermined). Because deaths might involve more than one 
drug, some deaths are included in more than one category. On death certificates, the specificity of of drugs 
involved with deaths varies over time. In 2014, approximately 19% of drug overdose deaths did not include 
information on the specific type of drug(s) involved.
c Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death 
certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity.
d Census regions are defined by the following jurisdictions: Region 1: Connecticut, Delaware, Maine, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Region 2: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, 
and Wisconsin; Region 3: Alabama, Arkansas, District of Columbia, Florida, Georgia, Kentucky, Louisiana, 
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West 
Virginia; Region 4: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming.
e Categories of 2013 NCHS Urban-Rural Classification Scheme for Counties  
(http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf):  
Socio-demographic 
Characteristic
Overall drug overdoses
Drug overdose deaths involving: 
Any opioidf
Natural and semi-
synthetic opioidsg Methadoneh
Synthetic opioids other 
than methadonei Prescription opioidsj Heroink Cocainel
Psychostimulants with 
abuse potentialm
Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
U.S. Census region of residenced
Northeast  9,077 16.1 0.172  5,961 10.7 0.141  1,851 3.3 0.078  587 1.0 0.044  1,485 2.7 0.071 2,337 4.1 0.087  2,755 5.1 0.098  1,439 2.6 0.07  223 0.4 0.029
Midwest  10,647 16.0 0.159  6,917 10.5 0.129  2,205 3.3 0.072  675 1.0 0.041  1,319 2.0 0.057 2,749 4.1 0.08  3,385 5.2 0.091  1,308 2.0 0.055  525 0.8 0.036
South  16,777 14.0 0.11  10,074 8.5 0.086  5,101 4.2 0.06  1,298 1.1 0.03  2,087 1.8 0.04 6,103 5.1 0.066  2,733 2.4 0.046  2,003 1.7 0.038  1,224 1.1 0.031
West  10,554 13.7 0.135  5,695 7.4 0.099  3,002 3.9 0.072  840 1.1 0.038  653 0.8 0.033 3,649 4.7 0.079  1,701 2.2 0.055  665 0.9 0.034  2,326 3.1 0.064
2013 Urbanizatione
Large Central 
Metropolitan
 13,714 13.5 0.116 8,301 8.1 0.091  3,214 3.1 0.056  985 1.0 0.031  1,330 1.3 0.036 3,992 3.9 0.063  3,793 3.7 0.061  2,231 2.2 0.047  1,555 1.5 0.039
Large Fringe 
Metropolitan
 11,676 14.8 0.139 7,550 9.7 0.113  2,739 3.4 0.066  772 1.0 0.036  1,626 2.1 0.053 3,368 4.2 0.074  3,171 4.2 0.076  1,350 1.8 0.048  694 0.9 0.035
Medium Metropolitan  10,486 16.0 0.16  6,378 9.9 0.126  2,883 4.4 0.084  809 1.2 0.044  1,255 2.0 0.057 3,518 5.4 0.092  2,114 3.4 0.074  1,124 1.7 0.053  981 1.5 0.049
Small Metropolitan  4,396 15.6 0.242  2,447 8.8 0.181  1,168 4.1 0.123  314 1.1 0.065  476 1.7 0.082 1,417 5.0 0.136  662 2.5 0.097  318 1.1 0.065  393 1.5 0.076
Micropolitan  4,138 16.0 0.256  2,442 9.6 0.2  1,277 4.9 0.141  308 1.2 0.072  537 2.1 0.095 1,509 5.8 0.154  567 2.3 0.1  273 1.1 0.069  418 1.7 0.083
Noncore  2,645 15.0 0.303  1,529 8.9 0.234  878 5.0 0.173  212 1.2 0.089  320 1.9 0.109 1,034 5.9 0.19  267 1.7 0.104  119 0.7 0.065  257 1.5 0.098
Intent
Unintentional  38,718 12.1 0.063  25,037 7.9 0.051  10,015 3.1 0.032  3,026 0.9 0.017  4,745 1.5 0.022 12,418 3.9 0.036  10,009 3.2 0.033  5,152 1.6 0.023  3,965 1.2 0.02
Undetermined  2,823 0.9 0.017  1,720 0.5 0.013  830 0.2 0.009  232 0.1 0.004  396 0.1 0.007 1,000 0.3 0.01  453 0.1 0.006  169 0.1 0.004  154 0.05 0.004
Suicide  5,433 1.6 0.023  1,843 0.5 0.013  1,296 0.4 0.011  137 0.04 0.004  395 0.1 0.006 1,398 0.4 0.012  93 0.01 0.002  82 0.01 0.003  164 0.04 0.004
Large central metro: Counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) 
contain the entire population of largest principal city of the MSA, or 2) have their entire population 
contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal 
city of the MSA; Large fringe metro: Counties in MSAs of ≥1 million population that did not qualify as large 
central metro counties; Medium metro: Counties in MSAs of populations of 250,000–999,999; Small metro: 
Counties in MSAs of populations less than 250,000; Micropolitan (nonmetropolitan counties): counties in 
micropolitan statistical areas; Noncore (nonmetropolitan counties): nonmetropolitan counties that did not 
qualify as micropolitan.
f Drug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic 
opioids (T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4) and other and 
unspecified narcotics (T40.6).
g Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
h Drug overdose deaths, as defined, that involve methadone (T40.3).
i Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
j Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2) and methadone 
(T40.3).
k Drug overdose deaths, as defined, that involve heroin (T40.1).
l Drug overdose deaths, as defined, that involve cocaine (T40.5).
m Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
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FIGURE 1A Trends in opioid prescribing — United States, 2006-2016
Annual prescribing rates by overall and high-dosage (≥ 90 MME/day) prescriptions 
Between 2006 and 2016, the annual prescribing rate per 100 persons decreased from 72.4 to 66.5 for 
all opioids, an overall 8.1% reduction. The annual percent change increased by 4.1% from 2006 to 2008 
(p<0.05), then increased another 1.1% from 2008 to 2012 (p<0.05), and then annually decreased by 4.9% 
from 2012 through 2016 (p<0.05).
Between 2006 and 2016, the annual prescribing rate per 100 persons decreased from 11.5 to 6.1 for high-
dosage opioid prescriptions, an overall 46.8% reduction (Supplemental Table 1). The rate leveled off between 
2006 and 2009, then annually decreased by 9.3% from 2009 to 2016 (p<0.05). 
Source: QuintilesIMS® Transactional Data Warehouse.
High-dose prescriptions were defined as opioid prescriptions resulting in a daily dosage of ≥ 90 MME.
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Annual prescribing rates by days of supply per prescription
From 2006 through 2016, the annual prescribing rate for thirty or more days’ supply per 100 persons 
increased from 17.6 to 27.3 for prescriptions with ≥ 30 days of supply, an overall 55.1% increase. The rate 
increased annually by 9.9% from 2006 through 2010 (p<0.05) and by 2.9% from 2010 through 2013 (p<0.05), 
and then annually decreased by 1.3% between 2013 and 2016 (p<0.05).
During 2006-2016, the annual prescribing rate for less than thirty days’ supply per 100 persons decreased 
from 54.7 to 39.2 for prescriptions with < 30 days’ supply, an overall 28.3% reduction. The rate leveled off 
from 2006 through 2008, then decreased annually by 1.2% between 2008 and 2012 (p<0.05), and further 
decreased annually by 7.3% from 2012 to 2016 (p<0.05).
Trends in opioid prescribing — United States, 2006-2016FIGURE 1B
Source: QuintilesIMS® Transactional Data Warehouse.
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Trends in opioid prescribing — United States, 2006-2016FIGURE 1C
Average daily morphine milligram equivalents (MME) per prescription
Between 2006 and 2016, average daily MME per prescription decreased from 59.7 to 47.1 for all opioids, an 
overall 21.1% reduction. The rate decreased annually by 1.0% from 2006 to 2010 (p<0.05), 4.7% from 2010 
to 2013 (p<0.05), and 1.7% from 2013 to 2016 (p<0.05).
Source: QuintilesIMS® Transactional Data Warehouse. 
Abbreviation: MME, morphine milligram equivalents. 
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Trends in opioid prescribing — United States, 2006-2016FIGURE 1D
Average days of supply per prescription
Between 2006 and 2016, average days of supply increased from 13.3 to 18.1 days per prescription, an overall 
35.7% increase. The rate increased annually by 4.4% from 2006 to 2008 (p<0.05), 3.4 % from 2008 to 2011 
(p<0.05), and 2.5% from 2011 to 2016 (p<0.05).
Source: QuintilesIMS® Transactional Data Warehouse.
Abbreviation: MME, morphine milligram equivalents. 
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Age-adjusted ratesa of drug overdose deathsb and drug overdose deaths involving any opioidc, 
for all intents and for unintentional intent, by year — United States, 1999–2015 FIGURE 2A
The rate of drug overdose deaths increased from 6.1 per 100,000 population in 1999 to 16.3 in 2015; for 
unintenttional drug overdose deaths, the rate increased from 4.0 per 100,000 in 1999 to 13.8 in 2015; for 
drug overdose deaths involving any opioid, the rate increased from 2.9 per 100,000 in 1999 to 10.4 in 2015 
(p<0.05); for unintenttional drug overdose deaths involving any opioid, the rate increased from 2.1 per 
100,000 in 1999 to 9.3 per 100,000 in 2015 (p<0.05). For all four categories of drug overdose deaths, increases 
in rates were largest from 2013 to 2015, with the rate increasing on average by 9% per year for overall drug 
overdose deaths (p<0.05), 11% per year for unintenttional drug overdose deaths (p<0.05), 15% per year 
for drug overdose deaths involving any opioid (p<0.05), and 16% for unintenttional drug overdose deaths 
involving any opioid (p<0.05). 
Source: National Vital Statistics System, Mortality File, CDC WONDER.      
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). All drug overdose deaths are identified using 
underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). Unintentional drug 
overdose deaths are identified using underlying cause-of-death codes X40–X44. Note that overall drug overdose deaths and opioid overdose deaths 
include deaths of any intent. In 2015, 5.7% of drug overdose deaths had undetermined intent; this is a decrease of 14.7% of drug overdose deaths 
with undetermined intent in 1999. Some of these deaths may be unintentional drug overdose deaths.   
c Drug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic opioids (T40.2), methadone (T40.3), other 
synthetic opioids excluding methadone (T40.4), and other and unspecified narcotics (T40.6). Specification on death certificates of drugs involved 
with deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include information on the specific type of drug(s) 
involved. Some of these deaths may have involved opioids.
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The rate of drug overdose deaths involving natural and semi-synthetic opioids increased from 1.0 per 
100,000 population in 1999 to 3.9 in 2015 (p<0.05); for those involving heroin, the rate increased from 0.7 
per 100,000 in 1999 to 4.1 in 2015 (p<0.05); for those involving synthetic opioids other than methadone, the 
rate increased from 0.3 per 100,000 in 1999 to 3.1 in 2015 (p<0.05); and for those involving psychostimulants 
with abuse potential, the rate increased from 0.2 per 100,000 in 1999 to 1.8 in 2015 (p<0.05). Rates of drug 
overdose deaths involving methadone declined from 1.8 per 100,000 in 2006 to 1.0 in 2015 (p<0.05), an 
average decrease of 7% per year; and for those involving cocaine, increased from 1.3 per 100,000 in 2010 to 
2.1 in 2015 (p<0.05), an average increase of 9% per year. Rates for drug overdose deaths involving natural 
and semi-synthetic opioids remained stable from 2010 to 2015 (p>0.05); while increases in drug overdose 
deaths involving synthetic opioids other than methadone were largest from 2013 to 2015 (p<0.05), with the 
rate increasing on average by 81% per year. Heroin rates increased on average 31% per year from 2010 to 
2015 (p<0.05), and death rates of psychostimulants with abuse potential increased on average 23% per year 
from 2008 to 2015 (p<0.05). 
Source: National Vital Statistics System, Mortality File, CDC WONDER.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Because deaths 
might involve more than one drug, some deaths are included in more than one category. Specification on death certificates of drugs involved with 
deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include information on the specific type of drug(s) involved. 
Some of these deaths may have involved opioids or stimulants.  
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined).     
c Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).  
d Drug overdose deaths, as defined, that involve heroin (T40.1).
e Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
f Drug overdose deaths, as defined, that involve cocaine (T40.5).
g Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
h Drug overdose deaths, as defined, that involve methadone (T40.3).
Age-adjusted ratesa of drug overdose deathsb, by drug or drug class and year —  
United States, 1999–2015FIGURE 2B
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Among persons ages 15 to 24 years, the rate of drug overdose deaths involving heroin was 3.8 per 100,000, 
and those involving synthetic opioids other than methadone was 2.3. Among persons ages 25 to 34 years, 
the rate of drug overdose deaths involving heroin was 9.7 per 100,000; those involving synthetic opioids 
other than methadone was 6.6; and those involving natural and semi-synthetic opioids was 5.3. Among 
persons ages 35 to 44 years, the rate of drug overdose deaths involving heroin was 7.4 per 100,000; those 
involving synthetic opioids other than methadone was 5.6; and those involving natural and semi-synthetic 
opioids was 6.9. Among persons ages 45 to 54 years and 55 to 64 years, the rate of drug overdose deaths 
involving natural and semi-synthetic opioids was 8.1 and 6.4 per 100,000 respectively; those involving 
heroin were 5.6 and 3.4, respectively; those involving synthetic opioids other than methadone were 4.6 
and 2.9, respectively. Rates of drug overdose deaths involving cocaine were 3.6 per 100,000 among 25 to 
34 year olds, 3.8 among 35 to 44 year olds, and 4.3 among 45 to 54 year olds. Rates of deaths involving 
psychostimulants with abuse potential were 3.0 per 100,000 among 25 to 34 year olds, 3.3 among 35 to 44 
year olds, and 3.5 among 45 to 54 year olds. 
Source: National Vital Statistics System, Mortality File, CDC WONDER.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Because deaths 
might involve more than one drug, some deaths are included in more than one category. Specification on death certificates of drugs involved with 
deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include information on the specific type of drug(s) involved. 
Some of these deaths may have involved opioids or stimulants.  
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined).     
c Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).  
d Drug overdose deaths, as defined, that involve methadone (T40.3).     
e Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4). 
f Drug overdose deaths, as defined, that involve heroin (T40.1).     
g Drug overdose deaths, as defined, that involve cocaine (T40.5).   
h Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
FIGURE 2C Age-adjusted rates
a of drug overdose deathsb, by drug or drug class and age category —
United States, 2015
CDC National Center for Injury Prevention and Control  |  2017Annual Surveillance Report of Drug-Related Risks and Outcomes  |  United States
72
FIGURE 2D
Source: National Vital Statistics System, Mortality File, CDC WONDER. 
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Rates are 
suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). On death certificates, the 
specificity of drugs involved with deaths varies over time. In 2014, approximately 19% of drug overdose deaths did not include information on the 
specific type of drug(s) involved.
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FIGURE 2E
Source: National Vital Statistics System, Mortality File, CDC WONDER. 
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Rates are 
suppressed when based on <20 deaths.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). On death certificates, the 
specificity of drugs involved with deaths varies over time. In 2015, approximately 17% of drug overdose deaths did not include information on the 
specific type of drug(s) involved.
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Opioid prescribing, United States, 2006-2016
SUPPLEMENTAL 
TABLE 1
Opioid Prescribing 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
% Change from 
2006 to 2016
Prescribing ratea             
All opioids 72.4 75.9 78.2 79.5 81.2 80.9 81.3 78.1 75.6 70.6 66.5 -8.1
High-dosageb 11.5 11.7 11.8 11.5 11.4 8.8 8.3 7.6 7.1 6.7 6.1 -46.8
Days of supply per Rx             
≥ 30 days 17.6 20.1 22.1 23.9 25.9 27.1 28.0 28.3 28.4 28.2 27.3 55.1
< 30 days 54.7 55.8 56.1 55.6 55.3 53.8 53.2 49.8 47.2 42.5 39.2 -28.4
Dosage (MME)             
Average daily MME per Rx 59.7 59.1 58.7 58.1 58.0 53.9 51.8 50.2 48.9 48.1 47.1 -21.0
Average MME per Rx 828.2 861.9 894.1 922.6 963.8 946.7 911.5 901.7 895.9 907.5 599.3 -27.6
MME per Capita 599.3 653.9 699.4 733.0 782.3 765.9 740.6 704.1 677.0 640.4 599.3 0.0
Average days supply per Rx 13.3 13.9 14.5 15.0 15.5 16.0 16.4 16.9 17.2 17.7 18.1 35.7
Source: QuintilesIMS Transactional Data Warehouse.
Abbreviation: MME, morphine milligram equivalents; Rx, prescription
a Rate per 100 persons adjusted to the U.S. census population.
b High-dose prescriptions were defined as opioid prescriptions resulting in a daily dosage of ≥ 90 MME.
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Estimated numberab and rate per 100,000 population of drug poisoning-related hospitalizations by selected substances — United States, 2014
SUPPLEMENTAL 
TABLE 2A
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic 
Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf Poisoning by other opioidsg Cocaine poisoningsh Methamphetamine poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All Visits 259,665 81.4 1.01 53,000 16.6 0.28 11,475 3.6 0.12 4,580 1.4 0.06 37,125 11.6 0.21 13,265 4.2 0.22 8,290 2.6 0.09
Sex
Male 114,590 73.0 1.07 25,880 16.5 0.34 8,080 5.1 0.18 2,460 1.6 0.08 15,445 9.8 0.22 8,990 5.7 0.32 5,405 3.4 0.14
Female 145,075 89.6 1.12 27,120 16.7 0.32 3,395 2.1 0.1 2,120 1.3 0.07 21,680 13.4 0.28 4,275 2.6 0.15 2,885 1.8 0.09
Age groups (years)
0-14 7,950 13.0 0.75 560 0.9 0.11 k k k 105 0.2 0.04 435 0.7 0.09 140 0.2 0.05 355 0.6 0.08
15-19 15,645 74.2 2.17 935 4.4 0.35 350 1.7 0.2 65 0.3 0.09 520 2.5 0.26 140 0.7 0.13 470 2.2 0.24
20-24 19,260 84.0 1.74 3,600 15.7 0.63 2,205 9.6 0.49 180 0.8 0.13 1,230 5.4 0.35 445 1.9 0.2 1,030 4.5 0.34
25-34 42,725 98.1 1.74 8,755 20.1 0.59 4,260 9.8 0.41 750 1.7 0.14 3,790 8.7 0.35 1,850 4.2 0.25 2,700 6.2 0.31
35-44 39,420 97.3 1.75 6,970 17.2 0.54 1,730 4.3 0.26 740 1.8 0.16 4,510 11.1 0.4 2,350 5.8 0.4 1,700 4.2 0.25
45-54 52,360 120.5 2.03 10,860 25.0 0.68 1,695 3.9 0.28 1,095 2.5 0.19 8,110 18.7 0.55 4,685 10.8 0.7 1,260 2.9 0.21
55-64 42,085 105.0 1.81 11,585 28.9 0.72 985 2.5 0.2 1,155 2.9 0.2 9,495 23.7 0.65 2,885 7.2 0.57 570 1.4 0.15
≥65 40,220 87.1 1.38 9,735 21.1 0.58 230 0.5 0.08 490 1.1 0.11 9,035 19.6 0.55 770 1.7 0.15 205 0.4 0.07
U.S. Census region of residence
Northeast 47,920 85.3 2.73 10,690 19.0 0.78 3,510 6.2 0.36 990 1.8 0.17 6,240 11.1 0.46 4,410 7.9 0.91 575 1.0 0.11
Midwest 57,800 85.3 2.26 11,250 16.6 0.62 3,345 4.9 0.33 865 1.3 0.12 7,070 10.4 0.4 2,340 3.5 0.32 1,300 1.9 0.16
South 101,450 84.7 1.66 19,610 16.4 0.43 2,900 2.4 0.15 1,575 1.3 0.08 15,170 12.7 0.37 5,325 4.4 0.32 2,925 2.4 0.14
West 52,495 69.8 1.75 11,450 15.2 0.55 1,720 2.3 0.16 1,150 1.5 0.11 8,645 11.5 0.44 1,190 1.6 0.18 3,490 4.6 0.27
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 or 
E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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Estimated numberab and rate per 100,000 population of drug poisoning-related hospitalizations by selected substances — United States, 2014
SUPPLEMENTAL 
TABLE 2A
Socio-demographic 
Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf Poisoning by other opioidsg Cocaine poisoningsh Methamphetamine poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
2013 Urbanization 
Large Central 
Metropolitan
78,000 79.6 2.79 15,515 15.8 0.66 3,950 4.0 0.26 1,585 1.6 0.12 10,045 10.3 0.45 7,080 7.2 0.6 2,795 2.9 0.18
Large Fringe 
Metropolitan
58,605 74.1 2.64 12,740 16.1 0.67 3,510 4.4 0.26 910 1.2 0.1 8,350 10.6 0.46 2,290 2.9 0.24 1,490 1.9 0.15
Medium Metropolitan 57,540 86.6 4.13 12,070 18.2 0.96 2,340 3.5 0.28 1,025 1.5 0.15 8,760 13.2 0.72 2,050 3.1 0.25 1,750 2.6 0.24
Small Metropolitan 25,790 88.3 5.05 4,860 16.6 1.08 730 2.5 0.27 400 1.4 0.16 3,745 12.8 0.87 620 2.1 0.27 925 3.2 0.4
Micropolitan 23,375 85.8 2.94 4,595 16.9 0.81 525 1.9 0.22 390 1.4 0.18 3,690 13.5 0.68 575 2.1 0.23 720 2.6 0.26
Not Metropolitan or 
Micropolitan
14,085 74.3 3.22 2,760 14.6 0.85 250 1.3 0.19 205 1.1 0.18 2,310 12.2 0.77 255 1.3 0.23 460 2.4 0.27
Unknown 2,270 460 170 65 225 395 150
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of injury 
E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 or 
E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
CONTINUED
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Estimated numberab and rate per 100,000 population of drug poisoning related emergency department visits by selected substances 
— United States, 2014
SUPPLEMENTAL 
TABLE 2B
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic 
Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf Poisoning by other opiodsg Cocaine poisoningsh Methamphetamine poisoningsi
Number Ratej SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE Number Rate SE
All Visits 418,313 131.2 4.17 92,262 28.9 1.82 53,930 16.9 1.5 2,921 0.9 0.07 35,690 11.2 0.41 6,424 2.0 0.18 11,012 3.5 0.14
Sex
 Male 199,999 127.4 4.74 57,655 36.7 2.58 38,035 24.2 2.17 1,554 1.0 0.09 18,242 11.6 0.49 4,462 2.8 0.29 6,752 4.3 0.22
 Female 218,313 134.8 3.86 34,607 21.4 1.14 15,894 9.8 0.86 1,367 0.8 0.07 17,448 10.8 0.38 1,962 1.2 0.09 4,260 2.6 0.11
Age groups (years)
 0-14 70,984 116.2 4.12 2,263 3.7 0.23 k k k 95 0.2 0.03 2,126 3.5 0.22 472 0.8 0.09 2,244 3.7 0.22
 15-19 46,755 221.8 7.19 4,170 19.8 1.16 1,796 8.5 0.79 64 0.3 0.08 2,321 11.0 0.63 226 1.1 0.17 1,318 6.3 0.45
 20-24 48,443 211.3 8.91 16,294 71.1 4.96 12,276 53.5 4.35 231 1.0 0.16 3,848 16.8 0.89 589 2.6 0.23 1,873 8.2 0.58
 25-34 80,785 185.5 9.12 30,478 70.0 5.72 22,411 51.5 4.99 675 1.6 0.16 7,503 17.2 0.9 1,662 3.8 0.39 3,051 7.0 0.43
 35-44 53,233 131.3 5.42 14,410 35.6 2.68 8,703 21.5 2.15 558 1.4 0.16 5,177 12.8 0.68 1,369 3.4 0.38 1,376 3.4 0.27
 45-54 50,116 115.3 4.44 12,328 28.4 1.91 5,869 13.5 1.45 575 1.3 0.15 5,929 13.6 0.61 1,250 2.9 0.41 734 1.7 0.15
 55-64 34,075 85.0 2.73 8,061 20.1 1.01 2,458 6.1 0.62 488 1.2 0.16 5,132 12.8 0.56 703 1.8 0.23 321 0.8 0.1
 ≥65 33,922 73.4 2 4,258 9.2 0.42 375 0.8 0.14 236 0.5 0.07 3,655 7.9 0.37 152 0.3 0.06 95 0.2 0.05
U.S. Census region of residence
 Northeast 83,450 148.6 14.49 27,462 48.9 7.96 20,570 36.6 6.8 585 1.0 0.19 6,356 11.3 1.28 1,105 2.0 0.24 1,125 2.0 0.17
 Midwest 100,900 148.9 8.44 24,944 36.8 4.16 16,162 23.9 3.4 433 0.6 0.1 8,437 12.5 0.9 1,127 1.7 0.21 2,377 3.5 0.24
 South 137,841 115.1 6.12 25,100 21.0 1.84 11,802 9.9 1.36 975 0.8 0.11 12,393 10.3 0.61 3,128 2.6 0.41 3,694 3.1 0.2
 West 96,122 127.9 6.5 14,756 19.6 1.33 5,396 7.2 0.7 929 1.2 0.15 8,504 11.3 0.67 1,063 1.4 0.27 3,816 5.1 0.44
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of 
injury E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 
or E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
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SUPPLEMENTAL 
TABLE 2B
a Weighted national estimates from HCUP Nationwide Inpatient Sample (NIS), 2014, Agency 
for Healthcare Research and Quality (AHRQ).
b In-hospital deaths and patients who transferred from another hospital were excluded. Visits 
with missing age and sex were excluded. Numbers subject to rounding error.
c includes ICD-9-CM principal diagnosis code of 960-979 (Poisoning by Drugs, Medicinal, and 
Biological Substances) or first listed cause of injury E850-E858 (Accidental Poisoning by 
Drugs, Medicinal Substances, and Biologicals).
d includes ICD-9-CM principal diagnosis code of 965.00, 965.01, 965.02, 965.09 or first listed 
cause of injury E850.0, E850.1, E850.2.
e includes ICD-9-CM principal diagnosis code of 965.01 or first listed cause of injury E850.0.
Socio-demographic 
Characteristic
All drug poisoningsc All Opioid poisoningsd Heroin poisoningse Methadone poisoningsf Poisoning by other opiodsg Cocaine poisoningh Methamphetamine poisoningi
Number Ratej SE Number Ratej SE Number Ratej SE Number Ratej SE Number Ratej SE Number Ratej SE Number Ratej SE
2013 Urbanization 
 Large Central 
Metropolitan
104,834 107.0 7.32 22,862 23.3 2.36 13,122 13.4 1.72 1,170 1.2 0.16 8,672 8.9 0.73 2,619 2.7 0.41 3,155 3.2 0.31
 Large Fringe 
Metropolitan
89,713 113.5 9.87 27,093 34.3 4.98 19,012 24.0 4.27 485 0.6 0.08 7,658 9.7 0.85 1,196 1.5 0.19 1,697 2.1 0.2
 Medium Metropolitan 111,082 167.1 11.78 23,438 35.3 3.78 13,468 20.3 2.9 625 0.9 0.11 9,425 14.2 1.08 1,514 2.3 0.25 2,919 4.4 0.33
 Small Metropolitan 40,317 138.0 14.37 7,143 24.5 4.15 3,330 11.4 2.97 222 0.8 0.13 3,600 12.3 1.48 430 1.5 0.3 1,199 4.1 0.48
 Micropolitan 41,919 153.8 6.71 6,776 24.9 2.09 3,084 11.3 1.65 178 0.7 0.13 3,529 13.0 0.76 316 1.2 0.19 1,069 3.9 0.31
 Not Metropolitan or 
Micropolitan
26,890 141.9 6.24 3,720 19.6 1.36 975 5.1 0.82 207 1.1 0.18 2,537 13.4 0.87 208 1.1 0.18 804 4.2 0.39
 Unknown 3,557 1,230 938 k 269 k 168
f includes ICD-9-CM principal diagnosis code of 965.02 or first listed cause of injury E850.1.
g includes ICD-9-CM principal diagnosis code of 965.09, 965.00 or first listed cause of 
injury E850.2.
h includes ICD-9-CM principal diagnosis code of 970.81 or first listed cause of injury E854.3 
or E855.2.
i includes ICD-9-CM principal diagnosis code of 969.72 or first listed cause of injury E854.2.
j Rates calculated per 100,000 population using the vintage year population of the data.
k The relative standard error was >30% or the standard error = 0, the value of the estimate 
was considered unreliable and was not reported.
CONTINUED
Estimated numberab and rate per 100,000 population of drug poisoning related emergency department visits by selected substances 
— United States, 2014
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Age-adjusted ratesa of drug overdose deathsb and drug overdose deaths involving any 
opioidc, for all intents and for unintentional intent, by year — United States, 1999–2015
SUPPLEMENTAL DATA 
SUPPORTING MORTALITY 
FIGURE 2A
Drug overdose deaths 
(of all intents)
Unintentional drug 
overdose deaths
Drug overdose deaths involving 
any opioid (of all intents)
Unintentional drug overdose 
deaths involving any opioid
Year Rate SE Rate SE Rate SE Rate SE
1999 6.1 0.047 4.0 0.038 2.9 0.032 2.1 0.028
2000 6.2 0.047 4.1 0.038 3.0 0.033 2.2 0.028
2001 6.8 0.049 4.6 0.040 3.3 0.034 2.4 0.029
2002 8.2 0.053 5.7 0.045 4.1 0.038 3.1 0.033
2003 8.9 0.055 6.3 0.047 4.5 0.039 3.4 0.034
2004 9.4 0.057 6.8 0.048 4.7 0.040 3.6 0.035
2005 10.1 0.059 7.6 0.051 5.1 0.042 4.0 0.037
2006 11.5 0.062 8.8 0.055 5.9 0.045 4.8 0.04
2007 11.9 0.063 9.1 0.055 6.1 0.045 5.0 0.041
2008 11.9 0.063 9.2 0.055 6.4 0.046 5.3 0.042
2009 11.9 0.063 9.4 0.056 6.6 0.047 5.5 0.043
2010 12.3 0.064 9.7 0.057 6.8 0.047 5.7 0.044
2011 13.2 0.066 10.6 0.059 7.3 0.049 6.3 0.045
2012 13.1 0.065 10.6 0.059 7.4 0.049 6.4 0.046
2013 13.8 0.067 11.3 0.061 7.9 0.051 6.9 0.048
2014 14.7 0.069 12.1 0.063 9.0 0.054 7.9 0.051
2015 16.3 0.072 13.8 0.067 10.4 0.058 9.3 0.055
Source: National Vital Statistics System, Mortality File, CDC WONDER.
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). All drug overdose deaths are identified using 
underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). Unintentional 
drug overdose deaths are identified using underlying cause-of-death codes X40–X44. Note that 5.7% of drug overdose deaths in 2015 had 
undetermined intent; this is a decrease of 14.7% of drug overdose deaths with undetermined intent in 1999. Some of these deaths may be 
unintentional drug overdose deaths. 
cDrug overdose deaths, as defined, that involve opium (T40.0), heroin (T40.1), natural and semi-synthetic opioids (T40.2), methadone (T40.3) , other 
synthetic opioids excluding methadone (T40.4), and other and unspecified narcotics (T40.6).
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Age-adjusted ratesa of drug overdose deathsb, by drug or drug class and year, 
United States, 1999–2015
SUPPLEMENTAL DATA 
SUPPORTING MORTALITY 
FIGURE 2B
Year
Natural and semi-
synthetic opioidsc
 Methadoned  
Synthetic opioids 
other than 
methadonee
 Heroinf  Cocaineg  
Psychostimulants 
with abuse 
potentialh
Rate SE  Rate SE  Rate SE  Rate SE  Rate SE  Rate SE
1999 1.0 0.019  0.3 0.010  0.3 0.009  0.7 0.016  1.4 0.022  0.2 0.009 
2000 1.0 0.019  0.4 0.011  0.3 0.010  0.7 0.015  1.3 0.021  0.2 0.009 
2001 1.2 0.021  0.5 0.013  0.3 0.011  0.6 0.015  1.3 0.022  0.2 0.009 
2002 1.5 0.023  0.8 0.017  0.4 0.012  0.7 0.016  1.6 0.023  0.3 0.011 
2003 1.7 0.024  1.0 0.019  0.5 0.013  0.7 0.016  1.8 0.025  0.4 0.012 
2004 1.8 0.025  1.3 0.021  0.6 0.014  0.6 0.015  1.9 0.025  0.4 0.012 
2005 1.9 0.026  1.5 0.023  0.6 0.014  0.7 0.015  2.1 0.027  0.5 0.013 
2006 2.3 0.028  1.8 0.025  0.9 0.017  0.7 0.016  2.5 0.029  0.5 0.013 
2007 2.7 0.030  1.8 0.025  0.7 0.015  0.8 0.016  2.2 0.027  0.4 0.012 
2008 3.0 0.031  1.6 0.023  0.8 0.016  1.0 0.018  1.7 0.024  0.4 0.012 
2009 3.1 0.032  1.5 0.023  1.0 0.018  1.1 0.019  1.4 0.022  0.5 0.013 
2010 3.5 0.034  1.5 0.022  1.0 0.018  1.0 0.018  1.3 0.021  0.6 0.014 
2011 3.7 0.035  1.4 0.022  0.8 0.017  1.4 0.022  1.5 0.022  0.7 0.016 
2012 3.5 0.034  1.2 0.020  0.8 0.017  1.9 0.025  1.4 0.022  0.8 0.017 
2013 3.5 0.034  1.1 0.019  1.0 0.018  2.7 0.030  1.6 0.023  1.2 0.020 
2014 3.8 0.035  1.1 0.019  1.8 0.024  3.4 0.034  1.7 0.024  1.4 0.021 
2015 3.9 0.035  1.0 0.018  3.1 0.032  4.1 0.037  2.1 0.026  1.8 0.024 
Source: National Vital Statistics System, Mortality File, CDC WONDER. 
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Because deaths 
might involve more than one drug, some deaths are included in more than one category.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined).  
c Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
d Drug overdose deaths, as defined, that involve methadone (T40.3). 
e Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
f Drug overdose deaths, as defined, that involve heroin (T40.1).
g Drug overdose deaths, as defined, that involve cocaine (T40.5).
h Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
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Age-adjusted ratesa of drug overdose deathsb, by drug or drug class and age category, 
United States, 2015
SUPPLEMENTAL DATA 
SUPPORTING MORTALITY 
FIGURE 2C
Source: National Vital Statistics System, Mortality File, CDC WONDER. 
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage year population of the data year. Because deaths 
might involve more than one drug, some deaths are included in more than one category.
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined).  
c Drug overdose deaths, as defined, that involve natural and semi-synthetic opioids (T40.2).
d Drug overdose deaths, as defined, that involve methadone (T40.3). 
e Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
f Drug overdose deaths, as defined, that involve heroin (T40.1).
g Drug overdose deaths, as defined, that involve cocaine (T40.5).
h Drug overdose deaths, as defined, that involve psychostimulants with abuse potential (T43.6).
* Rates are suppressed when based on <20 deaths
Age group (yrs)
Natural and 
semi-synthetic 
opioidsc
 Methadoned  
Synthetic opioids 
other than 
methadonee
 Heroinf  Cocaineg  
Psychostimulants 
with abuse 
potentialh
Rate SE Rate SE Rate SE Rate SE Rate SE Rate SE
0–14 0.1 0.011  --* --*  --* --*  --* --*  --* --*  --* --*
15–24 1.6 0.061  0.5 0.032  2.3 0.072  3.8 0.093  1.0 0.048  0.9 0.047 
25–34 5.3 0.109  1.7 0.061  6.6 0.122  9.7 0.148  3.6 0.090  3.0 0.082 
35–44 6.9 0.131  1.8 0.067  5.6 0.118  7.4 0.135  3.8 0.097  3.3 0.091 
45–54 8.1 0.137  2.0 0.067  4.6 0.103  5.6 0.114  4.3 0.100  3.5 0.090 
55–64 6.4 0.125  1.6 0.062  2.9 0.084  3.4 0.092  2.9 0.084  2.3 0.075 
≥65 1.5 0.057  0.3 0.024  0.5 0.032  0.4 0.028  0.4 0.029  0.3 0.027 
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Age-adjusted ratesa of drug overdose deathsb, by state, 2015
SUPPLEMENTAL DATA 
SUPPORTING MORTALITY 
FIGURE 2D
State of residence Age-adjusted rate SE  State of residence Age-adjusted rate SE
Alabama 15.7 0.589  Montana 13.8 1.22
Alaska 16.0 1.482  Nebraska 6.9 0.633
Arizona 19.0 0.544  Nevada 20.4 0.833
Arkansas 13.8 0.713  New Hampshire 34.3 1.716
California 11.3 0.168  New Jersey 16.3 0.435
Colorado 15.4 0.53  New Mexico 25.3 1.16
Connecticut 22.1 0.803  New York 13.6 0.264
Delaware 22.0 1.595  North Carolina 15.8 0.405
District of Columbia 18.6 1.686  North Dakota 8.6 1.129
Florida 16.2 0.294  Ohio 29.9 0.532
Georgia 12.7 0.356  Oklahoma 19.0 0.721
Hawaii 11.3 0.898  Oregon 12.0 0.55
Idaho 14.2 0.98  Pennsylvania 26.3 0.473
Illinois 14.1 0.335  Rhode Island 28.2 1.648
Indiana 19.5 0.562  South Carolina 15.7 0.582
Iowa 10.3 0.599  South Dakota 8.4 1.064
Kansas 11.8 0.668  Tennessee 22.2 0.592
Kentucky 29.9 0.853  Texas 9.4 0.187
Louisiana 19.0 0.663  Utah 23.4 0.932
Maine 21.2 1.338  Vermont 16.7 1.731
Maryland 20.9 0.593  Virginia 12.4 0.389
Massachusetts 25.7 0.63  Washington 14.7 0.455
Michigan 20.4 0.47  West Virginia 41.5 1.582
Minnesota 10.6 0.452  Wisconsin 15.5 0.535
Mississippi 12.3 0.67  Wyoming 16.4 1.729
Missouri 17.9 0.56     
Source: National Vital Statistics System, Mortality File, CDC WONDER. 
a Rate per 100,000 population age-adjusted to the 2000 U.S. standard population using the vintage 2015 population. 
b Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths are identified using underlying 
cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). 
